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Abstract 
 
 
The following study investigates the use of diagnostic ultrasound in 
combination with microbubbles (ultrasound contrast agents) as a physical 
enhancer for non-viral gene delivery. The aim of this work was firstly, to 
demonstrate that ultrasound exposure using settings within the range of diagnostic 
ultrasound, in combination with microbubbles can improve gene delivery, and  
secondly, to show that it is a safe, site-specific technique which mitigates the risk 
of tissue damage often seen with other physical enhancers of gene delivery such 
as, electroporation.  
 
Initially, a feasibility study was carried out to test the efficiency and safety 
of microbubble ultrasound (MBUS) in a reporter gene setting. Experiments using 
intravenous injections of a luciferase reporter gene established that MBUS is a 
safe, site-specific technique which improved levels of the luciferase expression in 
the organ targeted by MBUS. Luciferase was successfully delivered to the liver 
and heart, showing significantly higher levels compared to injections without 
MBUS, and with no detectable expression in other non-target organs. A 
therapeutic application of MBUS was tested using the mdx mouse, an animal 
model for Duchenne Muscular Dystrophy (DMD), a genetic disorder caused by 
the lack of functional dystrophin in muscle fibres due to premature termination of 
translation. The most successful treatment approach in the mdx mouse thus far 
had been the injection of Phosphorodiamidate Morpholino Oligomers (PMOs), 
which by inducing exon skipping, re-introduced dystrophin expression in most 
muscles in the body, with the exception of the heart. Injections of PMOs with 
MBUS to the heart successfully re-introduced dystrophin expression in 
cardiomyocytes. Furthermore, treatment parameters were investigated in more 
detail in order to optimize PMO delivery to the heart. Finally, an investigation 
into different types of commercially available microbubbles compared the 
efficiencies (with respect to gene delivery) of the different bubbles, in order to 
understand why different microbubbles show different results when used for 
MBUS, potentially enabling the design of microbubbles specifically for gene 
delivery.  
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1 Introduction  
 
1.1 Gene therapy – An overview 
 
Successful delivery of genetic material into cells could provide a valuable 
tool to treat a variety of diseases. The success of gene therapy largely depends on 
the availability of suitable delivery vehicles. Viral vectors have very good 
transfection properties, but there are concerns about the use of these vectors due to 
the possible induction of an immune response against viral proteins, a possible 
recombination with wild-type viruses, and the potential to be carcinogenic due to 
random integration in the genome1, 2. Some of the early clinical trials with viral 
vectors have highlighted the safety issues involved. In 1999, a patient died after 
he was treated for a mild form of the monogenic disorder ornithine 
transcarbamylase deficiency with a high dose of an adenovirus vector, which 
induced a fatal immune reaction3. 4 years later, a group of children treated for X-
linked SCID (severe combined immunodeficiency) developed T cell lymphoma 
after receiving a treatment with retroviruses, which was caused by insertional 
mutagenesis of the vector near a known cellular proto-oncogene (LMO2)4. Since 
then, much has been learned from these events and a lot of effort has been put into 
improving the safety of viral vectors. Recently, progress has been made in 
applying viral gene therapy in the clinic, especially for cancer treatments5-7. 
However, the long term safety of these therapies still has to be shown, and 
concerns regarding the use of viral vectors still remain. Unfortunately, a long term 
follow up on a clinical trial for X-linked SCID based in the UK has shown that 1 
out of the 10 children treated has developed a T cell leukemia, most likely due to 
insertional mutagenesis (http://www.esgct.org/upload/X-SCID_statement_AT.pdf, 
accessed 17.03.2008).  
 
In an attempt to improve safety of viral gene therapies, other replication-
defective vectors were investigated. Adeno-associated virus (AAV) vectors have 
been widely tested due to their ability to transduce a wide variety of tissue and to 
mediate a long term expression after a single in vivo administration8-10. AAV 
vectors are not associated with any disease pathology in humans, are naturally 
replication-defective and they are generally low in immunogenicity and are non-
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integrating11. Initial pre-clinical in vivo studies have shown that AAV has the 
potential to be a useful, safer alternative to retroviral gene therapies. However, 
further investigations in canine models have raised concerns about the safety of 
AAV vectors. Two studies in dystrophic dogs have shown that a single injection 
with AAV induced a strong immune response, which was sufficient to largely 
eliminate transgene expression12, 13. The observation that a single injection with 
AAV can induce a T cell response was also made in the first clinical studies11, 14. 
Therefore, further studies have to address and eliminate the issue of 
immunogenicity before AAV vectors can be safely applied in the clinic. A 
promising approach addressing the issue of immunogenicity was recently 
published by Wang et al., who showed that a course of an immunosuppression 
regime suppressed immune responses to both vector and transgene in a canine 
model15. 
 
An approach that is not linked to any safety concerns is the use of non-viral 
plasmid DNA for gene therapy. Advantages of non-viral plasmids are that they 
show low toxicity and they do not integrate into the genome at a level above 
background mutation rate or induce an immune response which allows repeated 
administration without causing an antibody response2, 16. The simplest approach 
for non-viral gene therapy is a direct injection with naked plasmid. After the 
discovery by Wolff et al. that reporter genes could be expressed following a direct 
injection of naked plasmid into skeletal muscle17, much interest has been given to 
direct injections with plasmid DNA. One particular focus was the generation of an 
antiviral immune response to plasmids encoding viral antigens, a potential new 
therapy called DNA vaccination. 370 clinical trials are registered to date for 
studies on DNA vaccines (February 2008, www.clinicaltrails.gov), a large 
proportion however use a combination with viral vectors for better efficiency, and 
some studies using naked DNA test the vaccine in combination with physical 
enhancers e.g. electroporation. This development away from naked DNA alone, 
also seen in pre-clinical studies for other applications18-22, emphasizes the main 
disadvantage regarding the use of non-viral plasmids. Efficiency of transgene 
expression after direct injections with non-viral plasmids is significantly lower 
compared to injections with viral vectors and highly inefficient when injected 
systemically, e.g. intravenously2. Naked DNA is unable to efficiently cross 
cellular barriers by passive diffusion due to its large size, strong negative charge, 
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hydrophilic nature and susceptibility to nuclease attacks23. Despite these issues, 
plasmid DNA is an attractive agent for gene therapy and a lot of research focuses 
on improving the efficiency of non-viral gene delivery. Attempts to enhance the 
delivery of non-viral plasmids can be split into two categories: chemical 
enhancers and physical enhancers. 
 
 
1.1.1 Chemical enhancers 
 
In order to improve non-viral gene delivery, DNA can be coupled with 
various types of synthetic vectors in an attempt to improve transfection efficiency. 
Moreover, these synthetic vectors attempt to improve the stability of plasmids 
during circulation in blood as well as their resistance against rapid metabolic 
clearance. The ones most extensively studied are cationic lipid- and cationic 
polymer-based systems24. Since the first successful in vitro transfection with 
cationic lipids was achieved by Felgner et al.25 a lot of progress has been made in 
this field. Direct injections of lipoplexes (cationic lipid/DNA complexes) have 
already been studied in clinical settings for the treatment of cancer and cystic 
fibrosis26, 27. However, efficiencies still need to be improved and only direct 
injections show potential. In vivo intravenous injections of lipoplexes show little 
gene transfection efficiency and solutions to problems such as rapid clearance by 
the reticuloendothelial system and the lack of target specificity are under 
investigation. Efforts have focused on modifying the cationic lipid structure28, 29, 
altering lipid formulations30, 31 and adding peptides32, 33 with specific 
functionalities. 
 
Synthetic vectors based on cationic polymers are also studied as a 
potential enhancer for non-viral gene therapy. Cationic polymers such as 
poly(ethylenimine) (pEI) and poly-L- lysine (pLL), compared to lipids, are more 
efficient in condensing DNA, but lack of control during synthesis often results in 
non-uniform polymer-DNA characteristics23. Furthermore, most cationic 
polymers show some cytotoxicity and in addition are non-degradable. 
Consequently accumulation in the body is a risk, especially after repeated 
injections34. The most promising advancement is the investigation into 
biodegradable polymers, which show lower cytotoxicity and a higher transfection 
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activity compared to pEI polyplexes34. However, no in vivo data has so far been 
reported. 
 
Although chemical enhancers have been successful in improving the 
cellular uptake of genetic material and progress is being made regarding their 
safety, one of the major drawbacks is that they are taken up by cells in a 
nonspecific manner when injected intravenously. Therefore, their use is mainly 
limited to local administrations. However, there is a need for gene therapy to be 
targeted even when the genetic material is administered systemically. 
 
 
1.1.2 Physical enhancers 
 
In order to enhance uptake of non-viral plasmid after direct and systemic 
injections several physical approaches have been developed: gene gun, 
electroporation, laser irradiation, and a hydrodynamic method. A hydrodynamic 
injection is a  rapid injection of a large volume through the portal or tail vein, 
which can give rise to high levels of gene expression in the mice, in particular in 
the liver24, 35, 36. Local applications in the leg were also successful in improving 
gene delivery into skeletal muscle37, 38. However, this application is not easy to 
translate into clinical practice, as a hydrodynamic injection can lead to transient 
decrease in heart function39. Moreover, it only shows potential for gene delivery 
to some organs, therefore application is limited. First clinical trials for 
hydrodynamic injections have started testing this approach on a single lobe of 
liver after blood flow in this lobe was blocked using a balloon catheter (Nagy 
Habib, personal communication). The other examples have a potential for a 
variety of clinical applications, although all of the examples discussed still need 
further optimization. 
 
The gene gun approach is a ballistic delivery, which uses heavy metal 
particles, usually gold beads, coated with DNA, which are propelled at a high 
velocity into the target cell40. The transfection area is limited by the shallow 
penetration of the plasmid, therefore skin has been the major target site, especially 
for DNA vaccination41-43. Other pre-clinical studies have involved target sites 
such as murine tumour44, liver45, 46, heart47 and embryo48. In a clinical setting, the 
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gene gun approach was used for treatment of hepatitis49, DNA vaccination50 and 
treatment of melanoma51 without severe toxicity. However, Klebe et al. have 
observed that during gene gun application, gold particles had ruptured the nuclear 
membrane of corneal endothelial cells, causing leakage of nuclear contents and 
cell death52.  
 
 Electroporation (also referred to as electropermeabilization or 
electrotransfer) introduces plasmid DNA into cells using electric pulses, which 
cause transient, localized destabilization of the cell membrane resulting in 
permeation structures53. The efficiency of this delivery approach is influenced by 
several factors, in particular pulse duration and the strength of the electrical 
field54. Different electrodes have been developed for several types of in vivo 
applications: surface electrodes, needle electrodes for deep tissue applications and 
electroporation catheters for hollow organs such as blood vessles55. The tissue to 
be transfected can be selected by placement of these electrodes. In order to 
improve the efficacy of electroporation, combination of electrical pulses were 
tested. It was found that the electrical pulses can have two roles: electroporation 
of the target cell and electrophoretic transport of the DNA towards or across the 
cell membrane53, 56, 57. New pulse generators are now able to deliver these 
combinations of pulses. The finding that eletrophoresis is involved was however 
questioned by Liu et al., who observed that pulses alternating in polarity were also 
efficient in improving gene delivery, which would allow the conclusion that 
electrophoresis does not play an important role in electro-gene transfer58. 
 
Electroporation can be applied to in vitro and in vivo systems, and has also 
been tested in clinical settings. In vivo a wide range of tissues have been studied 
including skin59, kidney60, lung61, liver62, skeletal muscle63, 64, spinal cord65, 
brain66, tumours67, 68 and the vasculature69. Electroporation has even been tested in 
the clinic for treatment of cancer, where it was able to improve the penetration of 
the chemotherapy agent through the cell membranes, with limited side effects70, 71. 
To date, 10 clinical trials for the use of electroporation are registered 
(www.clinicaltrials.gov, February 2008), 1 for DNA vaccination, 9 for cancer 
treatments. However, limitations of electroporation do exist. Most electroporation 
studies are in combination with direct injections of the plasmid DNA. Only few 
studies use electroporation with intravenous injections, although first successful 
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application have been reported in the liver72. Moreover, there can be substantial 
damage associated with the procedure2, which can limit the efficiency of 
transfection. Moreover, electrical pulses have also shown to cause vascular 
effects, which is the transient hypoperfusion of areas beyond the area targeted by 
the electrodes73. Modification of the strength and duration of the electrical pulse 
can improve, but not eliminate the associated problems. 
 
Laser irradiation has been reported to create transient pores in membranes, 
which are large but can rapidly self-repair74, 75. To date, gene delivery via laser 
irradiation has not been widely used, probably due to the high cost, the physical 
size of the laser sources, and the difficulties in controlling the appropriate 
conditions55. However, Zeira et al. have achieved gene transfer into skeletal 
muscle by application of a femtosecond infrared laser76. The mechanism by which 
laser irradiation improved gene delivery was not clear, but it was likely to involve 
local disruption of the muscle membrane. 
 
 Investigations into chemical and physical enhancers have dramatically 
improved the efficiency of non-viral gene delivery, which has transformed the use 
of plasmid vectors as a laboratory tool. Although some applications are already 
being tested in clinical settings, there are still concerns about the safety of these 
approaches and the issue of precise but even targeting of the tissue of interest has 
so far not been addressed adequately. Synthetic vectors improve delivery 
regardless of cell type or location, whereas physical enhancers are often limited to 
local applications, which do not necessarily allow even treatment of a whole 
organ. So far, the most likely areas of application will be for local administration 
to tumours and for enhanced genetic vaccination, as both applications can be done 
using direct injections and do not depend on delivery to be evenly distributed.  
 
There is a need to improve enhancers for gene therapy further to achieve a 
safe, efficient and easy to apply system to target the gene of interest to specific 
cells. Here, the use of diagnostic ultrasound in combination with contrast 
enhancing microbubbles is introduced as a safe, site-specific approach for non-
viral therapy. 
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1.2 Ultrasound History 
 
The use of ultrasound in medical diagnostics as we know it today has its 
roots in SONAR (Sound Navigation and Ranging) technology. The use of sound 
waves and their returning echoes to characterize objects inspired scientists to 
adapt this technique for medical purposes. After the first working SONAR system 
was built by Canadian Reginald Fessenden in 1914, it took almost 30 years until 
the first medical use of ultrasound was published. The use of ultrasound in 
medicine began with therapeutics rather than diagnostic applications. This was 
due to the discovery that heat generated by ultrasound had a disruptive effect on 
tissue. During the 1940s ultrasound was claimed to be a remedy for a list of 
conditions such as eczema, asthma, haemorrhoids and even angina pectoris, 
however without much scientific evidence. Around the same time, ultrasound was 
used experimentally as a possible diagnostic tool in medicine. The Austrian Dr 
Karl Theodore Dussik published the first work on medical ultrasound in 1942. He 
attempted to locate brain tumours and cerebral ventricles by measuring the 
transmission of the ultrasound beam through the skull. Dussik is generally 
regarded as the first physician to have used ultrasound in medical diagnosis77. 
 
From the mid 1940s on, the use of ultrasound in medicine was starting to 
develop around the world. In the 1950s, Professor Ian Donald and his team in 
Glasgow were leading the development of ultrasound technology and its 
applications. In the 1960s ultrasound systems began to become commercially 
available and rapid technological advances in electronics, in particular the 
invention of the microchip in the 1970s, lead to fast improvements, giving 
ultrasound systems increased processing power, better signal enhancement and 
new ways of displaying and interpreting the data77. 
 
 
1.3 Ultrasound Safety 
 
During the 1940s concern over potential tissue damage caused by 
ultrasound were raised, but to date there is no evidence that diagnostic ultrasound 
has caused harm to patients in the four decades that it has been used. However, 
high power and low frequency ultrasound has been shown to cause biological 
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effects, leading to the formation of transient, non-lethal perforations in cell 
membranes78-80. Currently, clinical scanners have two safety related indices, the 
thermal index (TI) and the mechanical index (MI). These are designed to provide 
the user with the relevant information in order to limit the possibility of bio-
effects occurring during diagnostic scanning. The TI stands for a measure of the 
energy absorbed by tissue from an ultrasonic beam. A high TI can cause the 
biological effects described above81. MI is an index for the mechanical effects that 
ultrasound may cause in the presence of gas bodies (section 3.1.1). Negative 
pressure in the ultrasound beam of sufficient magnitude can draw gas out of 
solution. The resulting gas bubbles then oscillate in response to the ultrasonic 
pressure field. This may lead to biological effects  locally, either from shear stress 
induced around the bubbles due to oscillation, or from the increased pressures, 
temperatures and in some cases microstreams/microjets created when the bubbles 
implode81-83. This latter phenomenon is known as inertial or collapse cavitation.  
 
In the USA, the Food and Drugs Administration has approved a maximum 
MI value of 1.9. An MI value of less than 1 indicates that mechanically induced 
damage is unlikely to occur81. Thus far, experimental and clinical data show that 
output levels of current diagnostic ultrasound scans are such that it is unlikely to 
produce any biological effects by cavitation mechanism, provided there are no gas 
bodies present in the exposed tissue81. TI and MI indices are only relevant 
however if ultrasound alone is used for diagnostic imaging. Changes due to use of 
contrast enhancing microbubbles have to be considered. 
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1.4 Microbubble History 
 
In 1968 Dr Claude Joyner made the chance observation during an 
angiographic cardiac study that injection of an iodinated contrast medium lead to 
an enhanced ultrasound signal84. Investigations into this phenomenon showed that 
this effect occurred with any injected liquid, especially so if some of the patient’s 
blood was drawn into the syringe first. Later, it was found that the enhancement 
resulted from gas bubbles in the injected liquid. Furthermore, the serum albumin 
in the patient’s blood acted to stabilize the air bubbles produced. Proof of this 
concept was provided when the enhancement was suppressed after the liquid was 
subjected to high pressure to remove any air bubbles in the syringe prior to 
injection. The first clinical application of this technique for diagnostic ultrasound 
used “shaken saline” (rapidly injected saline from one syringe to another, 
allowing traces of air to be incorporated as bubbles which were stabilized by a 
small amount of the patient’s blood). This was used to image right-to-left 
intracardiac shunts. However, the size of bubbles produced by this technique 
could not be regulated, therefore complications were frequent, such as paradoxical 
cerebral emboli, and sometimes associated death85. Research into albumin 
stabilized microbubbles eventually yielded the first commercial microbubble, 
Albunex (Mallinckrodt Inc., USA). Albunex was produced by high intensity 
sonication of an albumin solution. This was later followed by the more pressure-
resistant Optison (GE Healthcare), which like Albunex consisted of a human 
serum albumin shell, but unlike Albunex used the high-molecular-weight and 
sparingly soluble gas perfluorocarbon86. 
 
Using a different approach, microbubbles consisting of a disaccharide-based 
shell were developed, known as Echovist and Levovist87, 88. Echovist, 
unfortunately, was unstable once injected into the circulation, therefore it was not 
very useful as an enhancer for ultrasound imaging of intracardiac shunts. Levovist 
was later developed to contain a surfactant (palmitic acid), which improved 
stability. However, Levovist was not stable for long in circulation. This meant 
only studies of short duration were possible with Levovist. Another chance 
discovery however highlighted one very useful property of Levovist. Levovist 
persists for several minutes in the reticulo-endothelial system in the liver and 
kidney after it has been cleared from the blood pool89. This property makes it 
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useful in the detection of small lesions. Moreover, Levovist could also be used as 
a tracer to provide haemodynamic information by measuring the time from first 
appearance of the microbubbles in the hepatic artery to their arrival in the hepatic 
vein branch. This simple test can be used to discriminate between mild and severe 
forms of hepatitis and can separate hepatitis from cirrhosis90, 91. The most 
commonly used microbubble in clinics in the UK at the moment is a second 
generation microbubble called SonoVue (Bracco Diagnostics, Inc.). SonoVue is a 
suspension of highly flexible, phospholipid stabilized sulphur hexafluoride 
microbubbles. 
 
Recent development of clinically relevant ultrasound contrast agents are 
based on the fundamental understanding of the physics behind the enhancement of 
ultrasound, namely the impedance mismatch between the agent and the 
surrounding medium (blood). Gas has a large impedance mismatch with blood, 
which provides efficient backscatter of the sound waves transmitted by the 
ultrasound probe. This enables ultrasound imaging to detect blood flow. The gases 
usually chosen for microbubbles are high molecular weight gases such as 
perfluoro gas. Perfluoro gas is particularly advantages as its slow diffusion 
through the membrane prolongs the effective life of the bubble in the circulation. 
When microbubbles are present in an ultrasound field, they respond to the 
alternating compression and rarefaction cycles of the US wave by changing 
diameter, since their gas content is much more compressible than the surrounding 
tissue. This leads to scattering of the sound field. By fortunate coincidence the 
bubbles are extremely efficient scatterers as their natural resonant frequency 
matches that of the diagnostic frequencies typically used. At higher MIs the 
microbubble oscillations become asymmetrical, as the gas tends to resists 
compression but expands more easily. This results in a non-linear response that is 
then detected by the ultrasound scanner, and can be distinguished from the linear 
signal returned from tissue. 
 
 
1.5 Microbubbles today 
 
Microbubbles that are licensed for use in diagnostic imaging are small gas 
filled bubbles (typically about 3 µm in diameter) with albumin, lipid or polymer 
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based shells (Fig.1.1). The main application for microbubbles is to enhance 
visualization of blood. The detection of blood (or better, the bubbles in the blood) 
allows analysis of blood flow using Colour Doppler imaging techniques, and can 
detect abnormal appearance of blood vessels. As a consequence of intravenous 
administration of microbubble contrast agents, microbubbles have to have 
properties that allow them to survive in circulation. Microbubbles have to traverse 
the pulmonary capillary bed prior to the arrival at the imaging site. Therefore, an 
upper size limit of about 8µm diameter exists92. The microbubble membrane is 
also required to be stable enough to survive passage through the cardio-pulmonary 
circulation85 but flexible enough to resonate in the ultrasound beam. Therefore, 
for a microbubble to be clinically relevant, its size, membrane chemistry and 
entrapped gas have to be carefully adjusted so that it not only fits all the criteria, 
but can also be consistently reproduced. Moreover, the gas used and the 
membrane components have to be biologically inert to avoid problems associated 
with immunogenicity.  
 
Although originally developed as an ultrasound contrast agent for imaging, 
microbubbles are now under investigation as a promising tool for drug and gene 
delivery to cells. The idea that microbubbles can be used in such a way stems 
from the observation that bio-effects occur during ultrasound imaging when used 
in combination with contrast enhancing microbubbles93, 94. Studies into this bio-
effect have since shown the application of microbubble ultrasound can induces 
pore formation in cell membranes in a controlled way, leading to altered cell 
membrane permeability without causing significant damage to the cell95-98. 
Moreover, studies by van Wamel et al. suggest that these pores in the membrane 
only exist as long as the ultrasound field is present. Termination of the ultrasound 
results in the pores quickly resealing99. Therefore, the combination of 
microbubbles and ultrasound has the potential to improve gene delivery to cells, 
without causing permanent cell or tissue damage typically seen for other physical 
gene delivery methods such as electroporation2.  
 
While the properties of microbubbles for diagnostic imaging and therapeutic 
use may vary, it is clear more understanding of the mechanism by which 
microbubble ultrasound enhance gene or drug delivery is required, to enable them 
to be specifically designed for delivery applications. 
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Figure 1.1: Light microscopy image of Optison microbubble (diluted 1:100). 
Scale bar represents 50µm. 
 
 
 
1.6 Safety of Microbubbles 
 
1.6.1 Safety of microbubbles in circulation 
 
Several microbubbles have been approved by regulatory bodies after 
extensive clinical trials. Minor adverse effects have been reported in less than 5% 
of patients. These include transient discomfort at the injection site, taste 
aberrations and vaso vagal attacks. Some adverse effects were recorded for 
specific bubbles. For example, SonoVue was temporarily withdrawn due to three 
deaths that occurred following contrast echocardiography studies in patients with 
severe coronary artery disease. Due to the underlying instability of these patients 
it was suggested that the deaths were not related to the contrast agents, but caution 
was advised for patients with angina when SonoVue was reintroduced85. 
 
A more theoretical concern is linked to the use of human serum albumin 
(HSA) microbubbles such as Albunex and Optison. Although biologically inert, 
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there have been concerns over the possibility of transmitting viral or prion 
diseases due to the human origin of HSA. The process of microbubble production 
results in the denaturation of HSA limiting the likelihood of HSA acting as a 
potential source of viruses and prion proteins. Nevertheless, there still remains a 
potential risk. In light of this, ethics committees have insisted on clear labeling of 
the origin of the microbubbles shell, which has lead to a few patients refusing the 
use of this type of contrast agent.  
 
 
1.6.2 Safety of the microbubble in an ultrasound field 
 
Some serious adverse effects have been observed, including premature 
ventricular contractions, during echocardiography when US at high MIs were 
used during the sensitive end systole of the cardiac cycle. This effect was 
increased when high doses of contrast agent were used leading to the obvious 
recommendation to use low power MIs and low doses of contrast agents for 
echocardiography85.  
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1.7 In vitro investigations into the mechanisms of 
microbubble ultrasound 
 
1.7.1 Microbubble ultrasound and transient pore formation 
 
High power and low frequency ultrasound has been described to cause 
bio-effects, defined as transient, non-lethal perforations in cell membranes78-80. 
This process is also called sonoporation. Although sonoporation is not useful 
during diagnostic imaging, it is now under investigation as a potential tool for the 
delivery of drugs and genetic materials into cells. The transient pores produced by 
certain ultrasound energies allow larger molecules, such as plasmid DNA that 
would otherwise be excluded from accessing the cell, to pass into the cell interior. 
The mechanism of sonoporation is not yet fully understood, but ultrasound 
induced cavitation is the most likely explanation of the increased cell 
permeability100. Sonoporation has been shown to improve gene delivery in 
vitro101, 102 and in vivo103, 104. However, the energy required for sonoporation by 
ultrasound alone is greater than that permitted for diagnostic imaging, which is 
regarded as safe for clinical practice. Therefore, artificial cavitation nuclei, 
microbubbles, were used to potentiate the effect of lower energy ultrasound. 
 
Early experiments by Tachibana et al. investigated the use of the 
photosensitive drug merocyanine 540 (M540) as an enhancer for ultrasound 
induced pore formation. Ultrasound at 255kHz, 0.4W/cm2 for 30sec in the 
presence of M540 resulted in some cells exhibiting multiple surface pores. Other 
cells were found to lose membrane integrity, allowing the cytoplasm to extrude 
through the surface boundaries (Fig. 1.2 A-D). On other cells, microvilli on the 
cell surface disappeared and several flap-like wrinkles were seen (Fig. 1.2 F). 
These findings by Tachibana and colleagues were intended to demonstrate the use 
of this technique as a killing mechanism of tumour cells. However, they also 
proposes that this technique could also be used for selective delivery of genes or 
drugs into tumour cells105. Since then, the more prominent approach has been the 
use of microbubbles as a way of enhancing the effect of ultrasound for gene 
delivery. When microbubbles are present in a low energy ultrasound field with 
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power settings equivalent to those of diagnostic ultrasound systems, this can be 
sufficient to induce the bio-effects described. The exact mechanisms by which 
microbubbles and ultrasound cause transient pore formation are not yet fully 
understood. Two current models suggest possible mechanisms: inertial and stable 
cavitation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2: Scanning electron microscopic images of HL-60 cells. Irradiated with 
ultrasound in the presence of MC 540 (A to D), untreated intact cells (E), cells 
irradiated with ultrasound alone (F). Taken from Tachibana et al. 1999. 
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1.7.1.1 Model 1 - Pore formation by inertial cavitation 
 
Transient or inertial cavitation is the violent growth and collapse of a 
microbubble in an ultrasound field. At present, inertial cavitation is believed to be 
the primary mechanism for transient pore formation, due to the formation of 
microjets and microstreams during microbubble growth and collapse. 
 
In vivo studies by Tachibana et al. show that the effect of a thrombolytic 
agent can be enhanced by albumin microbubbles in conjunction with ultrasound, 
which they also attribute to violent microstreaming or microjets produced during 
microbubble collapse106. Further studies by Tachibana et al. suggest that these 
microjets or microstreams act to cause shear stress in the membrane of a nearby 
cell, thus disrupting the integrity of the membrane82, 83 (Fig. 1.3A). Another study 
by Hallow et al. observed that a reporter dye uptake after microbubble ultrasound 
(MBUS) treatment appeared in a pattern of discreet regions (patches), which they 
hypothesize to be caused by many individual cavitation events occurring near the 
cell surface107. Furthermore, Newman et al. postulates that inertial cavitation not 
only causes pore formation, but that the microjets may also inject’ the surrounding 
fluid into the cell. If this surrounding fluid contains a therapeutic agent, this 
combination of pore formation and ‘injection’ will lead to increased uptake of the 
agent108. 
 
When a bubble is located near a rigid boundary, liquid microjets develop 
during the final stages of bubble collapse. The migration of the bubble during 
collapse and the jet flow are both directed towards the boundary and thus, increase 
the damage range in this direction. The close proximity of the bubble to the 
boundary is essential for the effect of the liquid jet, as the liquid jet is strongly 
decelerated by the water layer between bubble and boundary. The shock wave that 
can be produced during collapse can generate pressures of 800atm, however, with 
increasing distance between bubble and boundary the maximum pressure 
produced will reduce109, 110.  
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Figure 1.3 : Models for pore formation caused by MBUS as proposed by (A) 
Tachibana et al. (2001) and Dijkman et al. (2004) with shear stress to the 
membrane due to microbubble collapse (B) Van Wamel et al. (2006) due to 
deformation of the membrane caused by the oscillating bubble. 
B 
A 
                 Resting Phase                       Expansion Phase 
 
                             Compression Phase                         
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In vitro experiments on cultured human skeletal muscle cells show 
electron microscope images immediately after cell transfection with MBUS 
(Optison, 1MHz, 2.5W/cm2 for 1min). The cells exhibit small holes in their 
surface, which sealed within 24hrs (Fig. 1.4). This formation of transient pores 
was only seen with the combination of ultrasound and microbubbles111. Although 
they do not speculate about the mechanism that leads to the formation of these 
pores, it is likely that pores of this size were caused by inertial cavitation of 
bubbles, rather than an oscillating bubble. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4: Electron microscope images of cultured skeletal muscle cells 
transfected with naked plasmid DNA using ultrasound and Optison (taken from 
Taniyama at el 2002). Control: untransfected cell. US+O: immediately after 
transfection of naked plasmid DNA using ultrasound with Optison. 24hrs: 24hrs 
after transfection of naked plasmid using ultrasound with Optison. Optison: cells 
transfected with naked DNA using Optison alone. US: cells transfected with 
naked plasmid DNA and ultrasound alone. Arrow indicates pore. 
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1.7.1.2 Model 2 – Pore formation by stable cavitation 
 
During stable cavitation, microbubbles exhibit sustained growth and 
oscillate over several acoustic cycles. In a proof-of-principle study Marmottant 
and Hilgenfeldt showed that stable cavitation is sufficient to achieve pore 
formation in lipid membranes, using bespoke microbubbles and fluorescently 
labeled lipid vesicles112. An in vitro study showed that oscillating microbubbles 
can cause cell deformation, which makes the cell permeable to small molecules 
that normally cannot penetrate. They suggest that the rapid movement of a stable 
oscillating bubble generates fluid flow over the cell membrane surface which 
could be responsible for the disruption of the cell membrane, thus creating a 
pore99 (Fig. 1.3B). 
 
Although this model was based on in vitro studies, earlier experiments 
show that rapid fragmentation of the bubble is necessary for pore formation. Chen 
et al. compared different ultrasound settings in vivo and concluded that the 
ultrasound power that causes the most bubble fragmentation yields the best gene 
delivery113. However, it is possible that a combination of both stable and transient 
cavitation is required to induce useful transient pore formation. Moreover, there 
might be further contributing factors that aid pore formation, such as a local 
temperature rise due to bubble oscillation114. However, at present the most 
favoured hypothesis is that inertial cavitation is the primary mechanism for 
transient pore formation. 
 
 
1.7.2 Reversibility of membrane damage 
 
Membrane damage caused by ultrasound is reversible and molecules that 
enter the cells remain trapped once the membrane reseals115. Estimates of the 
membrane recovery time range from a few seconds to at most a few minutes, and 
there is some evidence of separate pore populations that close at different rates108. 
Pore sizes are most commonly estimated to be in the range of 30 -100nm108.  
 
Current data suggests that ultrasound-mediated damage to cells 
membranes can be repaired. Schlicher et al. hypothesize that resealing of 
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ultrasound-induced pores is an energy (ATP) and Ca++ dependant mechanism that 
exhibits morphological features consistent with an active and vesicle-based 
wound-healing response by the cell116.  
 
 
1.7.3 Does MBUS enhance delivery into nucleus? 
 
So far, it is unclear whether microbubble ultrasound affects DNA entry 
into the nucleus. Many groups have found that MBUS only delivers DNA into the 
cytoplasm, with nuclear exclusion of any but the smallest molecules (which can 
gain access through nuclear pores)108. Kilo-and low megahertz ultrasound is 
unlikely to cause direct perturbations in the nuclear membrane. They suggest that 
this is most likely because any extracellular microbubble oscillation will be 
damped by the viscosity of the cytoplasm108. However, Duvshani-Eshet et al. have 
found that exposing baby hamster kidney cells to 0.16MI (1MHz) ultrasound for 
30 minutes in the presence of Optison yielded more DNA in the nucleus 
compared to a 10 minutes exposure96. However, it is not clear whether this 
demonstrates any influence on the nucleus, or whether the increased concentration 
in the cytoplasm simply shifted the gradient of DNA concentration from 
cytoplasm to nucleus over 30 minutes108. Moreover, they hypothesize that it is the 
ultrasound alone that drives the delivery of DNA to the nucleus, since addition of 
Optison during ultrasound exposure did not significantly increase DNA 
concentration in the nucleus96.  
 
 
1.7.4 Gene delivery beyond the endothelium 
 
An ex vivo study in arteries showed that bio-effects can be directed to the 
smooth muscle cells in the medial layer, suggesting that MBUS can have an effect 
beyond the endothelium117. However, bio-effects in these deeper layers were 
accompanied by loss of viability of these cells because of the high ultrasound 
intensities required to deliver the reporter dye into deeper layers. Moreover, they 
show that depth penetration is limited to the superficial layers of the tissue which 
they attribute to the limited penetration of the cavitation-mediated mechanism.  
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1.7.5 Summary 
 
Although many studies have attempted to find the underlying mechanism 
for MBUS, so far a detailed understanding of the process has still not been 
achieved, particularly in regards to the path of the gene or drug once inside a cell. 
Moreover, relating these finding to an in vivo setting opens another set of 
questions, especially relating to the endothelial layer. Taking into consideration 
that the consensus at this time is that microbubbles do not cross the endothelial 
layer, in vitro studies looking into the effect of cells in close proximity of 
microbubbles would only explain improved delivery to endothelial cells 
themselves. This does not explain why in vivo studies have been successful in 
delivering materials to a variety of cell types beyond the endothelial layer.  
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1.8 In vivo gene therapy using MBUS – An overview 
 
Gene delivery to specific organs has been investigated using a variety of 
approaches. Viral gene delivery using adeno-associated viruses has been shown to 
be very successful in the delivery of genes to the liver and heart118. However, the 
occurrence of adverse effects that are potentially fatal have lead to more interest in 
the development of a safer means of gene delivery. Physical methods that have 
been successful for delivering non-viral plasmids to the liver in animal models 
include electroporation119 and hydrodynamic injection35, 37, 120. The current 
hypothesis is that these methods are effective in enhancing non-viral plasmid 
delivery to the liver because they aid DNA transfer across the endothelial barrier 
119, 120
. Although these methods are currently being tested clinically (for example, 
electroporation in the treatment of skin cancer121) the damage caused as a result of 
such physical methods must be considered if these techniques are to be widely 
applied to gene therapy in humans. Moreover, studies into the effects of 
hydrodynamic injections suggest that the disruptive process observed in 
hepatocytes may not always be compatible with successful expression of 
delivered DNA120. Microbubble ultrasound however has the potential to aid gene 
uptake in a similar way by facilitating transfer across the endothelial barrier, while 
mitigating the damage caused. 
 
There is a wide variety of MBUS approaches described in the literature for 
use with both reporter and therapeutic genes. Most of those tested so far were 
carried out using an ultrasound frequency of 1-2MHz. Pressures, duty cycles, 
exposure times, microbubble types and time of analysis vary widely, which makes 
comparisons between studies difficult. An overview of studies investigating 
MBUS is shown in Tables 1 and 2. Surprisingly, almost all published data relates 
to the use of relatively high power ultrasound systems (see Tables 1 and 2), using 
power outputs well above that permitted for diagnostic imaging, and in some 
cases producing tissue damage in the rodent models which have been evaluated 
thus far. The trend towards the use of low frequency ultrasound is a response to 
several studies that show that lower frequencies are essential to successfully 
deliver and express genes in target cells. Chen et al. show that 1.3MHz ultrasound 
is more efficient than 5 or 12MHz ultrasound113. Careful consideration must be 
given to the different bubble types which have different shell properties and size 
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distributions, and may have different reactions to similar frequencies. Therefore, 
optimal ultrasound parameters should be evaluated for each bubble type. 
Furthermore, inertial cavitation caused by sonication of microbubbles with lower 
frequencies has to be carefully balanced against the potential to cause damage: 
lower frequencies may improve gene delivery, but they may also promote tissue 
damage. 
 
Several in vivo studies successfully provide proof-of-concept that MBUS 
can achieve therapeutic levels of gene expression. Ultrasound can improve gene 
uptake, when plasmid and microbubbles (commercial or bespoke) are injected 
directly into a target sites, such as muscle122, tumour98, liver123, heart124 or 
kidney125-127. Although these results demonstrate that the method can be 
successful, direct injections are not favoured for clinical use (e.g. direct injections 
into the liver, or injections requiring temporary cessation of blood flow), more so 
if repeat treatment is required108.  
 
Few studies have tried to inject DNA systemically and even fewer have 
used an IV injection, which would be the most compatible to clinical use. This is 
an exciting potential for MBUS, namely by injecting genetic material 
systemically, and using the ultrasound probe to direct transfection to the targeted 
area. The delivery of DNA molecules such as plasmids or oligonucleotides in 
conjunction with MBUS has the advantage of low toxicity and high target 
specificity and is minimally invasive, requiring only IV injection. A recent study 
by Chen et al. demonstrates that microbubble ultrasound provides a safe and 
efficacious way of delivering DNA constructs to beta cells of the pancreas when 
bubbles and DNA were infused into the internal jugular vein and ultrasound 
directed at the pancreas 128. Most studies utilising this approach consistently show 
that targeted MBUS can achieve expression restricted to the specified region, 
without any significant expression in the liver or other non-target organs, in 
contrast to viral vector transfers108. Moreover, studies show that the efficiency of 
MBUS is similar or better than viral or liposome mediated transfection113. On the 
downside however, the use of plasmid DNA results only in transient expression. 
Potentially, this could be prolonged with strategies avoiding promoter 
silencing108, but more likely MBUS treatment will have to be applied repeatedly. 
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Therefore, the safety of this approach is paramount for this technique to be used in 
patients.  
 
There is currently little data available on the use of diagnostic ultrasound 
imaging systems for transfection. However, it is likely that this would be a safe 
approach that reduces the tissue damage seen with other physical methods of gene 
delivery.  
 
The use of diagnostic ultrasound applied specifically to a target organ of 
interest while the genetic material is injected systemically, has the potential to 
increase gene uptake and reduce the non-specific expression in other tissue. Also, 
an advantage of this method is the possibility to image the process of transfection. 
Furthermore, this technology will minimise the amount of genetic material used, 
providing a safer method of gene delivery and a reduction in the costs of gene 
therapy.  
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Table 1.1: Summary of MBUS studies using reporter genes 
Authors Animal model Plasmid 
construct 
Microbubble Delivery method US  settings Optimal Expression Toxicity 
Pislaru et al. 
2003129 
Rat triceps brachii/ 
gastrocnemius 
Luciferase PESDA 20-200µg plasmid 
IM or 400µg 
plasmid IA 
(iliac/femoral 
artery) 
   
Christiansen et 
al 2003130 
Rat skeletal muscle Luciferase Bespoke 
cationic MB 
(plasmid 
attached) 
40µg MB coupled 
plasmid IV (jugular 
vein) or 4µg IA 
(femoral artery) 
1.75MHz, PW, MI 
1.9 (-1.14MPa) 
pulses every 7s for 15 
min 
Day 4: IA 200x better than 
IV 
Occasional 
micro-
haemorrages 
Li et al. 2003131 Mouse quadriceps GFP Albunex, 
Levovist, 
Optison 
25µg plasmid IM 1MHz, PW, 50% DC, 
2W/cm2 for 2 min 
Day 7: 10x increase using 
Optison vs. plasmid alone. 
No effect with Albunex or 
Levovist 
No inflammation 
or necrosis seen 
Lu et al. 200321 Mouse tibialis 
anterior (4 week and 
6 month old) 
GFP Optison 10µg plasmid IM 1MHz, PW, 20% DC, 
3W/cm2 for 60sec 
Day 7: 30x vs. plasmid 
alone in older mice 
Inflammation 
reduced by 
Optison + US 
Wang et al. 
2005132 
Mouse tibialis 
anterior (4-6 week 
old) 
GFP Optison, 
SonoVue, 
Levovist 
10µg plasmid IM 1MHz, PW, 20% DC, 
2W/cm2 for 30sec 
Day 7: 3x using SonoVue 
vs. plasmid alone 
No increased 
toxicity except 
with Levovist 
Chen et al 
2003113 
Rat myocardium Luciferase Bespoke 
liposome MBs 
containing 
plasmid 
Up to 600 µg of 
MB coupled 
plasmid IV (jugular 
vein) 
1.3MHz / 5 MHz / 
12MHz PW, MI 1.6-
2, ECG triggered pr 
continuous for 20 
min 
Day 4: Plasmid expression 
after MBUS equivalent to 
adenoviral MBUS. 
1.3MHz, MI 2 most 
effective. 
No LV 
dysfunction or 
negative 
inotropic effects 
 
Bekeredjian et 
al. 2003133 
 
 
 
Rat myocardium Luciferase  Bespoke 
albumin and 
lipid MBs 
containing 
plasmid 
350µg of MB 
associated plasmid 
over 20 min IV 
1.3MHz, PW, MI 1.5, 
ECG triggered for 20 
min 
Day 4: Peak expression 
over 28 day period. Re-
transfection successful 
Not reported 
Guo et al. 
2004134 
 
 
 
Mouse myocardium Luciferase 
and β- 
galactosidase 
Bespoke 
albumin 
bubbles (air 
filled) 
Up to 60µg 
plasmid IV (tail 
vein) 
1.3MHz, PW, MI 1.5 
for 2 min 
24hrs: 8x better than 
plasmid alone 
Transient 
elevation on 
cardiac enzymes 
Deleted: e
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Table 1.1 continued: Summary of MBUS studies using reporter genes 
 
Authors Animal model Plasmid 
construct 
Microbubble Delivery method US  settings Optimal Expression Toxicity 
Tsunoda et al. 
2005124 
Mouse myocardium Luciferase, 
β-
galactosidase 
GFP 
BR14, Optison 500µg plasmid 
direct into LV or 
IV (into tail vein) 
over 10sec 
1MHz, PW, 10-50% 
DC, 1-2 W/cm2 for 
20sec 
Day 4: Peak expression 
LV 60x better than IV 
when 50% DC and 
2W/cm2 for both bubbles  
BR14: 
Temporary 
aterioventricular 
block but no 
effect on 
contractility 
Optison:  caused 
death of some 
animals 
Azuma et al. 
2003125 
Mouse kidney Luciferase Optison 50µg plasmid 
infused into renal 
artery (performed 
ex vivo and 
retransplanted) 
2MHz, 2.5W/cm2, 
30sec for 8 min 
Day 4: 25x better than 
plasmid alone 
Not reported 
Lan et al. 
2003127 
Rat kidney FITC-
labelled 
oligonucleoti
des 
Optison 5µmol oligo into 
renal artery 
(MBUS performed 
in situ) 
1MHz, CW, 5% 
power output for 60 
sec 
45min: 95% glomerular 
and 70-80% tubular cells 
positive for FITC. 1000x 
better than oligos alone 
No histological 
or functional 
abnormalities 
Koike et al. 
2005126 
Rat kidney Luciferase Optison 
(>25% v/v) 
50µg plasmid into 
renal artery 
(MBUS performed 
in situ) 
1MHz, PW, 20% DC, 
3W/cm2 for 60sec 
Day 7: peak expression 
100x better than plasmid 
alone 
Histological 
damage due to 
high Optison 
concentration 
Duvshani-Eshet 
et al. 2007135 
Mouse tumour 
(flank) 
Luciferase , 
GFP 
10% Optison 100µg plasmid 
intratumoral  
1MHz, 30% DC, 
2W/cm2 for 20 min 
Day3: Luciferase: peak 
expression 2.5x better than 
plasmid alone. GFP: 10x 
better than plasmid alone 
Soma 
background 
expression 
detected in skin 
exposed to 
MBUS, not 
histological 
damage detected 
Deleted: e
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Table 1.2: Summary of MBUS studies using therapeutic genes 
 
Authors Animal model Plasmid construct Microbubble Delivery method US  settings Optimal Expression Toxicity 
Kondo et 
al. 
2004136 
Rat: acute left 
coronary artery 
ligation 
Plasmid encoding 
human hepatocytes 
growth factor, CMV 
promoter 
20% (v/v) 
Optison 
infused at 
0.2ml/min for 
5min IV 
1500µg plasmid 
via IV catheter in 
1.5ml over 1.5min 
1.3MHz, PW, end 
systole, -2.1MPa for 
2-4 min 
Up to 4x higher HGF 
expression vs. plasmid 
alone. More homogenous 
distribution. Improved 
function and angiogenesis. 
Myocardial scar reduced by 
>100% 
No difference 
in mortality 
compared to 
non MBUS 
animals 
Zhingan
g et al. 
2004137 
Rat: left anterior 
descending 
coronary artery 
ligation 
Plasmid encoding 
VEGF 
Quanfuxian 
(albumin/perfl
uorocarbon) 
2000µg plasmid IV 1.8MHz, PW, 
maximum MI, ECG 
triggered 
Significant enhancement in 
VEGF expression and 80% 
increase in capillary density 
in ischaemic myocardium 
Not reported 
Sakakim
a et al. 
2005115 
Nude mice: 
subcutaneous 
hepatocellular 
carcinoma 
Plasmid encoding 
human interferon-β, 
CMV promoter 
BR14 50µg into tumour 1MHz, 50% DC, 
2W/cm2 for 10 min 
Tumour growth reduced by 
70% over 6 weeks 
compared to tumour not 
receiving MBUS 
No toxic 
effects 
observed 
Akuwua
h et al. 
2005138 
Porcine saphenous 
vein interposition 
grafts into carotid 
artery 
Plasmid encoding 
human tissue 
inhibitor of 
metalloproteinase 3, 
CMV promoter 
BR14 (50% 
(v/v)) 
Segments of vein 
instilled and bathed 
in plasmid at 
33µg/µL 
1MHz, PW, 6% DC, 
1.8MI for 2 min 
>50% increase in lumen 
area in TIMP-3/MBUS 
group compared to controls 
US alone 
associated with 
increased 
neointima 
formation 
Miao et 
al. 
2005123 
Wild-type mice – 
hepatic transfection 
Plasmid encoding 
human factor IX, 
liver specific 
promoter 
Bespoke MBs 50µg injected 
directly into liver 
1MHz, PW, -4MPa Factor IX levels of up to 
63ng/mL (near therapeutic), 
66x compared to plasmid 
alone 
Transient mild 
liver 
inflammation 
 
Chen et 
al. 
2006128 
 
 
 
Rat, normal 
pancreatic islets 
Plasmid encoding (a) 
human insulin and (b) 
hexokinase, rat 
insulin 1 promoter 
Bespoke 
phospholipids 
MB carrying 
plasmid 
250µg MB coupled 
plasmid over 20 
min IV 
1.3MHz, PW, MI 
1.2-1.4, ECG 
triggered for 20 min 
for 20 in focused on 
pancreas 
(a) Up to 20x serum insulin/ 
C-peptide for 5-10 days and 
20% reduction in serum 
glucose. (b) 4x increase in 
serum insulin and 30% 
reduction in serum glucose 
No histological 
evidence of 
pancreatic 
inflammation, 
no change in 
serum amylase 
or lipase 
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1.9 Drug delivery with MBUS  
 
All forms of drugs that are delivered systemically have to be carefully 
balanced to be within an effective therapeutic range while minimizing any 
harmful side effects. Some drugs however, need high concentrations at a specific, 
site which cannot be achieved using systemic administration. This is especially 
the case in cancer therapies, where effective treatment is not always possible 
because of adverse effects of the drugs when administered systemically. 
Localizing the drug release at the tumour holds the promise of allowing more 
locally aggressive treatment. 
 
MBUS has the potential to improve the therapeutic index (ratio of median 
lethal dose the LD50, and median effective dose the ED50) by localizing drug 
release to a targeted area139. This could be achieved by loading the drug into or 
onto microbubbles and releasing it by rupturing the microbubbles in a localized 
ultrasound field. This would result in a higher local concentration while keeping 
the systemic concentrations low82. In addition to the localized release, there might 
also be enhanced delivery into the adjacent cells by the transient pore formation 
caused by MBUS.  
 
Depending on the type of drug (water soluble, hydrophobic, size), delivery 
with MBUS has to be tailored as not all delivery methods may be appropriate. 
There are several different approaches for successful drug delivery with MBUS. 
 
 
1.9.1 Co-injection of Drug and Microbubbles 
 
A drug can be co-injected with microbubbles while ultrasound is applied 
to a target area as a means of targeted drug delivery. This form of delivery only 
makes use of transient pore formation in the MBUS field, through which the drug 
could enter the cell. This approach is only effective for drugs of low toxicity and 
those not naturally taken up by cells as the drug will be injected directly into the 
circulation.  
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The first use of MBUS as an in vivo treatment going into clinical trials was 
the co-injection of thrombolytic enzymes and microbubbles for enhanced 
thrombolysis in treatment of ischemic stroke139. Tachibana and Tachibana 
originally proposed that the ultrasound vibration in conjunction with high 
compressibility of microbubbles would enhance the efficiency of thrombolysis by 
increasing the penetration of fibrolytic agents into the thrombus and thus 
accelerating fibrinolysis82, 106, 139. Recent pre-clinical studies focus on optimisation 
of this technique, finding optimal US settings and microbubble parameters82, 140. 
 
Further studies using the co-injection approach have been tested in vivo 
using reporter particles. Price et al. demonstrate that fluorescently labeled polymer 
particles and red blood cells can be effectively delivered to the interstitium of rat 
skeletal muscle through ruptured microvessels caused by the insonification of 
mircobubbles141, 142. Moreover, co-injection of drug and microbubble serves to 
minimize the amount of drug needed for a treatment. Sonoda et al. have 
demonstrated in an in vivo mouse model that a much lower dose of the anti-cancer 
drug bleomycin is needed when combined with MBUS in order to achieve tumour 
growth suppression143. 
 
 
1.9.2 Drug carried within the lipid shell of the microbubble membrane  
 
Hydrophobic drugs can be suspended within the lipid shell of a bubble, 
though the volume of drug that can be suspended within the microbubble shell is 
limited139. However, an additional oil layer can be used to increase the drug 
volume per bubble. Unger et al. showed that paclitaxel, a chemotherapeutic drug 
with activity against breast cancer, ovarian carcinomas, lung cancer and other 
tumours, can be suspended in soybean oil144. The oil can be agitated together with 
a gas, causing the gas to become entrapped inside the microdroplets of oil. These 
microdroplets can then be further stabilized by an outer coating of phospholipid 
amphiphiles (Fig. 1.5). Once these bubbles encounter an ultrasound field, they 
will burst releasing the drug. Moreover, the ultrasound signal released by the 
bursting bubbles could potentially be used to monitor and assess drug delivery by 
ultrasound imaging144. 
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Figure 1.5: Schematic representation of a microbubble consisting of a drug 
carrying oil layer around a gas core, stabilised by an outer phospholipids layer. 
Taken from Unger et al. 1998 
 
 
1.9.3 Drug attached to the shell electrostatically or via other interactions 
 
Hydrophilic drugs (e.g. protein based drugs) and DNA-based molecules 
may be attached to the bubble shell via electrostatic or covalent bonds. As 
described above, the drug would be released upon ultrasound mediated 
microbubble destruction in the region of interest. This technique has been 
successfully applied to plasmid DNA charge-coupled to cationic lipid 
microbubbles via the DNA’s negatively charged sugar phosphate groups130. In 
this study, gene transfection of cardiac and skeletal muscle was achieved using 
ultrasound and a microbubble bearing a luciferase plasmid.  Furthermore, 
Mukherjee et al. have used this approach to deliver vascular endothelial growth 
factor (VEGF) to the heart. They show that VEGF bound to albumin bubbles 
(here PESDA) together with ultrasound applied to the heart can augment VEGF 
delivery 13-fold compared to systemic administration without MBUS145. 
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However, if molecules are attached to the outside of the bubble shell, careful 
consideration has to be given to the stability of the interaction, as the microbubble 
construct has to pass through, and survive, transit through the pulmonary 
microcirculation. 
 
 
1.9.4 Carrier particles (liposomes) attached to bubble surface 
 
In this technique, the drug is packed into liposomes, which are attached to 
the outside of a microbubble shell (Fig. 1.6). This allows the packaging of a large 
amount of hydrophilic or hydrophobic drugs onto a microbubble, with more than 
1000 liposomes per microbubble146. It has been shown in vitro that a vibrating 
bubble can rupture a liposome that lies a short distance away112. Therefore, it 
seems likely that the efficiency of liposome rupture would be increased if the 
liposome is juxtaposed to the microbubble membrane and subjected to an 
ultrasound field139. Kheirolomoom et al. have recently shown in an in vitro 
setting, that these hybrid vesicles can effectively transfer a fluorescent agent into 
cells that are in the focus of an ultrasound field146. However, attaching the 
liposomes to the microbubble is most commonly done using avidin-biotin 
interactions. Repeated injections of avidin-biotin could lead to immune reactions 
in vivo, therefore a safer method of attaching liposomes to bubble will be 
required146. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 1.6: Schematic representation of a microbubble carrying liposomes on its 
surface. Taken from Kheirolomoom et al. (2007) 
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1.9.5 Drug inside thick polymer-shell air filled-bubbles 
 
A further approach to use microbubbles as a drug delivery system is to use 
microbubbles primarily as a slow-release drug delivery agent. Thick microbubble 
shells, such as biodegradable polymer based shells, can incorporate freeze-dried 
water-soluble materials within its gas core. The thick shell protects the material 
from external water and other potentially harmful influences in the blood (e.g. 
nucleases), until ultrasound pulses cause it to rupture and release the water-soluble 
material into the blood at the region of interest139, 147. The materials used in this 
approach have excellent storage stability in the dry state, and only need to be 
reconstituted with water immediately before use139. Hauff et al. have successfully 
used this approach in vivo for the delivery a plasmid encoding for β-galactosidase 
into mouse tumours, and have also shown the effectiveness of a tumour 
suppressor gene therapy using the same delivery approach147. 
 
   
The long-term fate of any particle delivered, even if inside a carrier has to 
be evaluated for each drug in detail. Microbubbles are often taken up by the liver 
and spleen or other unpredictable sites and so toxic effects will have to be closely 
monitored in any experimental setting in vivo139. 
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1.10  Aim of this study 
 
Successful delivery of genetic material into cells could provide a valuable 
tool to treat a variety of diseases. Viral vectors often transduce cells efficiently, 
but issues of high immunogenicity and the potential to be carcinogenic due to 
insertional mutagenesis have raised concerns about the safety of this approach. 
Non-viral plasmids have low toxicity and immunogenicity, however systemic 
administration of non-viral plasmid is often inefficient. Physical methods, such as 
electroporation are able to increase the transfection efficiency of non-viral vectors, 
but can cause extensive tissue damage. The aim of this study is to investigate the 
potential of diagnostic ultrasound in combination with microbubbles as a physical 
enhancer for the use of safe and site-specific gene delivery, in order to improve 
the efficiency of non-viral gene therapy. In this study, reporter gene experiments 
as well as a therapeutic example will be used in order to test the following 
hypotheses: 
 
• Microbubbles in combination with diagnostic ultrasound will improve the 
uptake efficiency of genetic material at a specific target when delivered in 
a systemic manner, with minimal non-specific expression. 
 
 
 
• Gene delivery with microbubbles and diagnostic ultrasound will be safe to 
apply allowing repeated treatments. 
 
• Microbubbles combined with diagnostic ultrasound will improve the 
delivery of antisense oligonucleotides to mdx myocardium. 
 
• Different microbubble types have different efficiencies for gene delivery 
with diagnostic ultrasound, which can be linked to a specific parameter. 
 
The following discourse describes in detail the experiments and approaches 
undertaken in an effort to test these hypotheses. The implications of these 
investigations in terms of their potential as a physical enhancer for non-viral gene 
therapy is discussed.  
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2 Materials and Methods 
 
Unless stated otherwise, all chemicals and reagents were purchased from Sigma, 
Fisher or BDH. 
 
 
2.1 Measurements of ultrasound parameters 
 
In a waterbath, the ultrasound transducer (either 15L8 or 7v3c) of the 
Siemens Acuson Sequoia ultrasound scanner and a membrane hydrophone were 
aligned 1cm apart. The focus of the ultrasound beam was set at 1cm. Ultrasound 
pulses transmitted by the scanner were detected using the hydrophone (Marconi 
Research Centre, UK) and data was recorded using a digital oscilloscope 
(TDS7154, Tektronix, Beaverton, OR). Data was recorded as mean peak 
frequency and transmitted pressure. 
 
 
2.2 Plasmids 
 
pEGFPluc (Clontech Laboratories, USA) containing a fusion of enhanced 
green fluorescent protein (EGFP) and luciferase from firefly Photinus pyralis 
driven by a CMV promoter was used. For JAC1 see Section 3.2.2. Plasmid DNA 
was amplified and purified using Qiagen Endo-Free Giga Prep (Qiagen) according 
to the manufacturer’s instructions and re-suspended in dH2O. Purified plasmids 
were quantified by spectroscopy at 260 nm and purity was determined by 
260nm/280nm ratio.  
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2.3 Restriction digests and ligations 
 
Restriction digests of plasmids were set up as 50µL reactions containing 
2µg plasmid DNA, 10-15 units restriction enzyme, 5µL 10x Buffer and 43µL 
dH2O. Digests were incubated at 37ºC for 2 hours. Klenow reactions were 
performed by adding 0.01µmol dNTPs and 1 unit Klenow enzyme (Invitrogen, 
UK) to the 50µL reaction, which was incubated for 15 minutes at 37ºC. Digests 
were purified using Qiagen Plasmid Purification Kit according to the 
manufactures instruction. For ligations, the open plasmid cassette and the insert 
were put together in three reactions with 1:1, 1:3 and 1:6 molar ratios, 
respectively. Molar ratios were determined by agarose gel electrophoresis. To 
each reaction, 1 unit T4 DNA ligase (Invitrogen, UK), 10µL 5x Ligase buffer and 
dH2O were added to a final volume of 50µL. The ligation solution was incubated 
at 15ºC for 3 days. 
 
 
2.4 Competent cell production and transformation 
 
A starter culture of competent cells (CC) (XL-1 Blue, Stratagene) was 
prepared in 5mL LBSOC (50mL LB broth, 0.5mL 1M MgSO4, 0.1mL 20% 
glucose) and incubated over night at 37°C. The starter culture was transferred into 
500mL LBSOC and grown until an OD600 of 0.6-0.7 was achieved. The culture 
was harvested at 5000 × g at 4ºC for 10 minutes and the pellet re-suspended in 
5mL LBSOC after which a further 25mL LBPEG (LB broth containing 3.6% 
(v/v), 1.2% (w/v) PEG, 0.12% 1M MgSO4) was added. CCs were stored at -70ºC 
until use. CC (100µL) were carefully mixed with 10µL of ligated plasmid or 20ng 
native plasmid and incubated for 10-15 minutes on ice. After a 3 minute heat 
shock at 42ºC, the mixture was put back on ice for 2 minutes and then transferred 
into 1mL LBSOC and incubated for 1 hour at 37ºC with agitation.  The culture 
(100µL) was plated out on agar containing the appropriate antibiotic (Ampicillin, 
100µg/mL for JAC1 and Kanamycin, 50µg/mL for pEGFPluc) and incubated over 
night. 
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2.5 DNA gels and plasmid gel extraction  
 
Native plasmids, plasmid and PCR fragments were run on 1% Agarose 
gels (unless stated otherwise) containing 0.5% EthBr. Appropriate volumes of 
DNA solution were mixed with 20µL loading buffer (65% (w/v) Sucrose, 10mM 
Tris-HCl (pH 7.5), 10mM EDTA, 0.3% (w/v) Bromophenol Blue) and loaded 
onto the gel. A current of 80V was applied for 1 hour. DNA was visualised using 
a UV light source. Following plasmid fragment separation bands of interest were 
excised and placed in dialysis tubing containing TBE. The tubing was subjected to 
an electric current (80V) until all DNA had migrated out of the gel. The gel was 
then discarded and the remaining solution dialysed against LSB (20mM Tris pH 
7.5, 1mM EDTA, 200mM NaCl) for 12 hours. The LSB was replaced and dialysis 
continued for an additional hour. The solution was transferred into a micro-
centrifuge tube and the DNA concentrated by precipitation with ethanol. 
 
 
2.6 Microbubbles 
 
All microbubbles used were commercially available and licensed for 
diagnostic imaging use in humans. Microbubbles used were Optison® (GE 
Healthcare), an albumin-coated octafluoropropane gas filled bubble, SonoVue® 
(Bracco Diagnostics, Inc.), a stabilised sulphur hexafluoride microbubble 
surrounded by a phospholipid shell and SonazoidTM (GE Heathcare) a lipid-
stabilised perfluorocarbon microbubble. If microbubbles required reconstitution, 
this was done according to manufacturer’s instructions, unless stated otherwise.  
Optison was concentrated by centrifugation at 8000rpm for 1 minute. 
Concentration and size distribution of all microbubbles was determined 
experimentally in Chapter 6. 
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2.7 Plasmid administration with microbubble ultrasound 
 
All animal experiments were performed under the authority of UK Home 
Office A(sp)A Project License PPL 70/6228. Mice were provided with food and 
water ad libitum in a Home Office approved controlled environment facility. 
Four- to five-week-old female C57BL10 mice (all averaging 18-20g body weight) 
were anaesthetised by injection using Hypnorm (Janssen Animal Health, UK) and 
Hypnovel (Midazolam, CP Pharmaceuticals Ltd., UK) and then injected 
intravenously (IV) with a mixture of plasmid DNA and microbubbles while 
ultrasound was applied to the organ of interest.  Unless stated otherwise, 
~1.2×108bubbles/mL microbubbles in a volume of 150µL were mixed with 
plasmid in a volume of 50µL (total volume 200µL) for IV injections. Ultrasound 
was applied with a Siemens Acuson Sequoia (Mountain View, CA, USA) clinical 
diagnostic ultrasound scanner using a 15L8-S probe for 2 minutes, unless stated 
otherwise. A 2 minute exposure time was chosen as this time period was 
identified to be the time the majority of microbubbles persisted in the blood 
stream. The transmitted ultrasound frequency was 7MHz while the system detects 
the non-linear harmonic signals from the microbubbles at 14MHz.  The amplitude 
of the transmitted pulses was set to a mechanical index (MI) of 1.8-1.9.  
 
Hair in the area of ultrasound application was removed with hair removal 
cream prior to application. Control mice were injected without microbubbles 
and/or ultrasound as appropriate. In some cases control mice were injected 
intramuscularly (IM) into the Tibialis anterior (TA) with differing amount of 
plasmid without microbubble ultrasound. 24 hours to 3 months after plasmid 
administration, in vivo reporter gene expression was analysed using a 
Bioluminescence Camera (Xenogen IVIS 100). After final bioluminescence 
analysis mice were sacrificed by cervical dislocation and organs of interest 
harvested, mounted on cork blocks and snap frozen in isopentane cooled in liquid 
nitrogen and stored at -80ºC for further analysis.  
 
 
Deleted: of 
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2.8 Bioluminescence imaging of Xenogen Calibrated Light 
Source using Xenogen IVIS 100 
 
Calibrated Light Source XLS-4 (Xenogen, USA) was turned on and 
allowed to stabilize for 1 minute at room temperature prior to imaging. The 
emitting light source was then placed in the centre of the field of view. Images 
were taken every minute for 30 minutes using a 20 second exposure time, f stop = 
1 and high resolution binning.  
 
 
2.9 In vivo bioluminescence imaging using Xenogen IVIS 100 
 
Mice were injected intraperitoneally (IP) with 300 mg/kg Luciferin 
substrate (Xenogen, USA), dissolved in Dulbecco PBS (injections with less than 
300mg/kg resulted in subobtimal luciferase activity, therefore 300mg/kg was 
chose for all injections). 30 seconds – 1 minute after substrate administration mice 
were anaesthetised with isoflurane and imaged using Xenogen IVIS 100 
Bioluminescence Imaging System (Xenogen, USA) for 2 minutes to 5 minutes 
depending on signal intensity. Data from luciferase expression was recorded in a 
region of interest as photons of light emitted per second (p/sec). 
 
 
2.10 Antisense oligonucleotide delivery to the heart with 
microbubble ultrasound 
  
Four- to five-week-old male and female mdx were anaesthetised as 
described before. Anaesthetised mice were then injected IV with 16 mg/kg 
Phosphorodiamidate Morpholino Oligomers (PMOs, Gene Tools Llc) together 
with Optison® (approximately 7.5×107 microbubbles) in a total volume of 200 µl. 
Ultrasound was applied to the site of interest as described before for 2 minutes 
post injection. 24 hours to 3 month after injection mice were sacrificed and organs 
of interest harvested and snap frozen in cold isopentane and stored at -80ºC for 
further analysis.  
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2.11 Immunohistochemistry 
  
Skeletal muscle and myocardium were taken, mounted on cork blocks as 
previously described and snap-frozen in liquid-nitrogen cooled isopentane and 
stored at -80 ºC. Sections of 7µm were cut from at least two thirds of the muscle. 
Dystrophin expression was examined by immunohistochemistry with polyclonal 
antibody P7 against C terminal dystrophin (kindely provided by Dr QL Lu) 
detected by goat-anti-rabbit Igs Alexa 594 (Molecular Probes, Cambridge, UK). 
Sections were counterstained with DAPI. The maximum number of dystrophin 
positive fibres in one section was counted. 
 
2.12  Histology 
 
7µm sections were cut from at least two thirds of the organ and fixed in 
4% paraformaldehyde. Slides were stained with haemotoxilin (Gill’s haemotoxilin 
containing glycol, BDH) for 3 minutes, washed in dH2O and then stained in eosin 
solution (1%w/v eosin, 0.4% w/v erythrosine B and 0.2% w/v Phloxine B in H2O) 
for 1 minute and washed again in dH2O. Dehydration was performed by 
incubating slides in 70% and 90% ethanol for 30 seconds each and 100% ethanol 
for 2x 30 seconds. Slides were then incubated in histological clearing agent Histo-
ClearTM (National Diagnostics) for 2x 30 seconds. Slides were air dried and 
mounted with DPX mounting medium (R.A. Lamb Lab Supplies).  
 
 
2.13 RNA extraction and RT-PCR 
  
Frozen sections were cut and collected and homogenized in Trizol 
(Invitrogen, UK) using an Ultra-Turrax homogenizer (Janke & Kunkel, 
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Germany). Total RNA was then extracted and 200ng RNA template was used for 
a 25 µl RT-PCR reaction with Qiagen One-Step RT-PCR-Kit (Qiagen, West 
Sussex, UK). The primer sequences for the initial RT-PCR reaction were Ex20Fo 
5’-CAGAATTCTGCCAATTGCTGAG-3’ and Ex26Ro 5’-
TTCTTCAGCTTGTGTCATCC-3’ (Invitrogen) for amplification of mRNA from 
exon 20 to 26. The cycling conditions were 95 ºC for 1 minute, 55 ºC for 1 minute 
and 72 ºC for 2 minutes for 30 cycles. 1µL RT-PCR product was used as the 
template for nested PCR reaction (primer sequences Ex20Fi 5’-
CCCAGTCTACCACCCTATCAGAGC-3’ and Ex26Ri 5’-
CCTGCCTTTAAGGCTTCCTT-3’) performed in a 25µL volume with 0.25 units 
of Taq DNA polymerase (Invitrogen). The reaction mix comprised of 1x PCR 
buffer, 10mM of dNTP, 0.6 µM of primer and 2.5mM MgCl2 (Invitrogen). The 
cycling conditions were 95°C for 1 minute, 55°C for 1 minute and 72°C for 2 
minutes for 30 cycles. Products were examined by electrophoresis on a 1.5% 
agarose gel.   
 
 
2.14  Protein Extraction and Western Blot 
 
Sections were collected from frozen tissues samples and lysed with 200µL 
protein extraction buffer containing 75mM Tris-HCl (pH6.8), 10% SDS, 5% 2-
mercaptoethanol. The mixture was boiled for 5 minutes and centrifuged for 15 
minutes at 15,000rpm. The supernatant was collected and the protein 
concentration quantified by Protein Assay Kit (Bio-Rad). Protein, 5µg from wild 
type C57BL10 mice as positive control and 100µg of protein from muscles of 
treated or untreated mdx mice were loaded onto a 6% polyacrylamide gel 
containing 0.2% SDS and 10% glycerol. Samples were electrophoresed at 120V 
for 4 hours and blotted onto nitrocellulose membrane at 45V for 12-15 hours. The 
membrane was washed and blocked with 5% skimmed milk for 1 hour and probed 
with 1:200 Dys-1 (monoclonal antibody against dystrophin, Vector Laboratories 
Inc. CA, USA) for 2 hours. The primary antibody was detected by HRP 
conjugated rabbit anti-mouse Igs (Dako Cytomation, Denmark) and ECL Plus 
Western Blotting Analysis System (GE Healthcare).  
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2.15 Counting and sizing of microbubbles 
 
For sizing and counting of microbubbles, microbubble solutions were 
made up according to manufacturer’s instructions, unless stated otherwise. The 
microbubble solution was then diluted into an appropriate volume in order to 
avoid aggregation of microbubbles for accurate counting. Unless stated otherwise, 
a 1 in 100 dilution was used. 10µL of the diluted solution was counted and sized 
using a standard haemocytometer (Bright-Line, Hausser Scientific, UK). The 
process was automated using a MATLAB based software designed for this 
application (Dr R. Eckersley, Imperial College London, UK).  
 
 
2.16 Bubble destruction experiments 
 
For microbubble destruction studies, the 15L8 transducer of the Siemens 
Acuson Sequoia was part immersed in a beaker filled with 200mL PBS at 37°C 
containing 2.5×105bubbles/mL (independent of microbubble type) (Fig. 6.5). A 
stirrer ensured equal distribution of the microbubbles. Ultrasound was then 
applied to the beaker for 20 seconds with a H14MHz, MI1.8 setting and a focus at 
3cm. Ultrasound images were saved before and after ultrasound application on a 
C14MHz, MI 0.59 setting. Images of a control group were taken at the same time 
points without receiving US exposure. Changes in the grayscale were detected 
using a MATLAB based software designed for this application (Dr R. Eckersley, 
Imperial College London, UK). 
 
 
2.17 Statistical analysis 
 
For comparison of two groups a standard unpaired t test was used. For 
comparisons of more than 2 groups, ANOVA analysis was used followed by  the 
Tukey test. 
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3 Experimental Methodology 
 
3.1 Establishing suitable ultrasound methodology 
 
3.1.1 Background 
 
There are two key ultrasound properties that play an important role in the 
acoustic behaviour of a bubble: Frequency and negative pressure (Fig. 3.1).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Basic ultrasound wave. Annotations depict which part of the wave is 
described as frequency, amplitude and negative pressure. 
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The frequency determines the rate at which the sound pressure field oscillates 
and oscillating pressure will in turn induce microbubble oscillation. If the 
microbubble is in an ultrasound field that is at or below its resonance frequency 
(specific to each bubble) the bubble will oscillate more strongly in the sound field and 
may be more likely to collapse. Therefore, the closer the ultrasound frequency is set 
to the resonance frequency of the microbubble, the higher is the chance for inertial 
cavitation.  
 
Positive pressure contributes to how much a bubble shrinks during oscillation 
in an ultrasound field. However, oscillation may not be symmetrical as the 
microbubble expands easier than it collapses. Therefore the peak positive pressure, 
which forces the bubble to collapse, plays an important role in causing inertial 
cavitation. If the ultrasound frequency is very close to, or below, the microbubbles 
resonance frequency, only a very low peak positive pressure is required to cause 
inertial cavitation. If the ultrasound frequency is higher than the resonance frequency, 
a higher peak positive pressure is needed for inertial cavitation to occur. The 
importance of the relationship between pressure and frequency for inertial cavitation 
is reflected in the safety index MI (mechanical index, see section 1.3) 
 
f
PMI
−
=
 
 
The higher the MI, the higher the chance for inertial cavitation of a bubble, therefore  
the higher the frequency, the higher the peak negative pressure has to be to cause 
inertial cavitation148.  
 
Frequency and negative pressure are limited by the design of the ultrasound 
machine and the ultrasound transducer. Therefore, the limitation of both has to be 
known, and for that range, the suitable ultrasound settings (frequency and negative 
pressure) have to be determined. 
Deleted: Negative 
Deleted: P
Deleted: e
Deleted: negative 
Deleted: negative 
Deleted: negative 
Deleted: negative 
 59
3.1.2 Determination of ultrasound transducer and settings 
 
In order to decide on a suitable ultrasound setting to use for the delivery of 
genetic material in vivo, the most appropriate transducer for this task had to be 
determined, as each transducer has its own specific range of possible settings. The 
two transducers that were available and which were in the right size range for the 
scanning of a mouse were transducers 15L8 and 7V3c (Fig. 3.2). The 7V3c 
transducer is smaller and therefore might not be able to allow equal scanning of the 
whole organs, especially for larger organs such as the liver. To get optimal coverage 
of a mouse organ it was believed that the 15L8 transducer was most appropriate. 
Moreover, the resolution of the 15L8 transducer is significantly better than the 7V3c. 
This is due to the 15L8 probe transmitting a shorter wavelength resulting in an 
improved resolution compared to the 7V3c prove which transmits at a longer 
wavelength. Due to the better resolution, the 15L8 transducer would allow much 
more accurate scanning. Therefore, the 15L8 transducer was thought to be the most 
useful for the purpose of MBUS gene delivery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.2: Transducers available on the Siemens Acuson Sequoia Ultrasound 
Scanner. (A) 15L8 transducer. (B) 7V3c transducer.  
A B 
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As discussed earlier (section 1.7.1) it is the consensus at this time that cavitation 
plays a primary role in effective delivery of genetic material by MBUS. Therefore the 
lowest frequency with the highest peak negative pressure was chosen for the 15L8 
transducer. The smallest frequency that can be transmitted by this transducer is 7MHz 
at an H14MHz setting (H: Harmonics mode). In Harmonics mode the ultrasound is 
detected at twice the frequency as transmitted. So at H14MHz, ultrasound is 
transmitted at 7MHz and detected at 14MHz. As this frequency is not close to the 
resonance frequency for the majority of the microbubbles within the population 
(Optison’s resonance frequency was measured to be 1.9 – 2MHz149), the highest peak 
negative pressure possible is chosen. It has to be considered, that due to the size 
distribution of the microbubble population, the smallest bubbles may have a 
resonance frequency closer to 7MHz compared to the larger microbubbles. This 
however means that these small bubbles may undergo inertial cavitation even easier 
in a high negative pressure ultrasound field, and therefore, choosing the highest peak 
negative pressure should force most microbubbles to undergo inertial cavitation. 
 
On the ultrasound scanner used (Siemens Acuson Sequoia) the peak negative 
pressure is not a parameter that can be set directly. However, the mechanical index 
(MI) can be changed, which is directly related to the peak negative pressure (P-) and 
frequency (f): 
 
f
PMI
−
=
 
 
If the MI is set to 1.8, which is the highest output possible at H14MHz, the peak 
negative pressure can therefore be calculated to be: 
 
MHz
P
7
8.1
−
=  
MPaMHzP 76.478.1 =×=−  
 61
3.1.3 Verification of ultrasound settings 
 
As described above, the negative pressure transmitted by the ultrasound 
scanner is a crucial parameter for the MBUS delivery mechanism. The MI setting, 
which is the only way of controlling the transmitted negative pressure on the Acuson 
Sequoia, is primarily an index for the safety of the chosen setting, hence displays a 
‘worst case scenario’ rather than an accurate measurement. In order to validate MI 
and negative pressures transmitted by the ultrasound scanner, and therefore know 
more accurately what ultrasound parameters the microbubbles are subjected to in 
vivo, a membrane hydrophone was used to measure frequencies and pressures 
transmitted by the 15L8 transducer for verification of MI and peak negative pressures 
(section 2.1). 
 
As can be seen from Table 3.1, the measured MI values vary from the MI that 
is given by the ultrasound scanner, and so does the measured peak negative pressure 
at H14MHz / MI 1.8 (numbers highlighted in red in table 3.1 compared to values 
calculated in section 3.1.2). However, it has to be considered that these measurements 
were done in a waterbath and do not relate exactly to in vivo conditions. 
Microbubbles in vivo would be subjected to negative pressures lower than the ones 
measured with the hydrophone, as the tissue that has to be penetrated attenuates some 
of the signal before it arrives at the microbubbles in e.g. the heart or liver. The 
measured values however, give a more accurate account of the settings than the 
values displayed by the scanner itself. 
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Table 3.1: Measurements of ultrasound outputs of 15L8 transducer sending a fixed 
frequency of 7MHz (H14MHz) with changing MIs. f : Frequency, −P : peak negative 
pressure. 
 
Set MI Peak f (MHz) Mean f (MHz) +P (MPa) −+  −P (MPa) −+  Measured MI 
0.06 5.9 6.1 0.03 0 0.04 0 0.01 
0.21 5.9 6.1 0.16 0 0.16 0 0.07 
0.33 5.9 6.1 0.27 0 0.26 0 0.11 
0.47 5.9 6.1 0.41 0 0.38 0 0.16 
0.66 5.9 6.1 0.61 0 0.55 0 0.23 
0.83 5.9 6.1 0.8 0 0.71 0 0.29 
1 5.9 6.1 1.09 0.01 0.93 0.01 0.38 
1.3 5.9 6.1 1.46 0.01 1.19 0.01 0.48 
1.6 5.9 6.1 2.05 0.02 1.54 0.01 0.63 
1.8 5.9 6.1 2.4 0.02 1.73 0.02 0.71 
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3.1.4 Ultrasound duty cycle measurement 
 
In order to be able to compare our settings better to the settings previously 
used in the literature, the duty cycle of the scanner was determined experimentally. 
The duty cycle is defined as the time the ultrasound is transmitting versus the time it 
is off. For example, a 50% duty cycle would mean that the ultrasound is being 
transmitted for 50% of the time, e.g. for 0.5sec per 1sec (Fig. 3.3). 
 
The representation of a duty cycle in Figure 3.3 is accurate for therapeutic 
ultrasound systems, however, diagnostic ultrasound transmission is not as straight 
forward. In a diagnostic system, the ultrasound is primarily sent out to establish an 
image. This image is produced by an ultrasound beam sweeping across the region of 
interest, focusing at a determined point (Fig. 3.4). Because of this sweeping motion, 
not all pulses transmitted hit the point of interest with the same intensity. And 
because of this, only pulses with amplitudes of 50% of the maximum amplitude were 
included in this estimate.  
 
From the settings of the Acuson Sequoia it is known that the images were 
formed at a rate of 70 times a second (70Hz). In order to determine the duty cycle of 
this scanner, the number of pulses that are send out during one of these sweeps was 
measured with a membrane hydrophone (section 2.1) and the width (duration) of the 
individual pulses was determined (Fig. 3.5).  
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Figure 3.3: Two different examples of a 50% ultrasound duty cycle. 
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Figure 3.4: Simplified schematic representation depicting the ultrasound beam 
sweeping across an area of interest. The blue lines are representative for an 
ultrasound pulse in the beginning (red), the middle (blue) and the end (green) of a 
sweep. The grey circle represents an area of interest within ultrasound field. 
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Figure 3.5: Ultrasound pulses as detected by a membrane hydrophone and visualised 
by an oscilloscope. (A) One set of ultrasound pulses that is send out 70 times a 
second by Siemens Acuson Sequoia at a H14MHz/MI 1.8 setting. (B) Zoomed in on 
one of the ultrasound pulses from (A). Arrows indicate the 50% limitation (of the 
maximum amplitude) applied for the measurements of number and width of the 
pulses seen. 
 
A 
B 
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It was determined that a sweep contains 6 individual pulses (Fig.3.5B) and 
each of these pulses (over 50% of the maximum) is on for 0.5µsec. Using these 
measurements the duty cycle of the pulses of this setting can be determined. 
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3.1.5 Potential sources of variation 
 
With regards to the ultrasound application and the microbubbles injected, 
there are two main sources of variation that can be identified. Firstly, microbubbles 
will be injected intravenously (IV) into the tail vein of a mouse. Due to human error, 
the injection may not go into the tail vein but rather the tail itself. If this occurs, 
pressure may build up in the syringe due to the resistance when the fluid is injected 
into the tail, which is rigid and does not easily accommodate the injected fluid. This 
pressure build up in the syringe may cause microbubbles to rupture, possible altering 
bubble number and size distribution compared to injections where the injectate was 
directly injected into the vein. Moreover, if the tail vein is missed, the total volume of 
fluid injected when injection goes into the tail vein on second attempt is lower than 
intended, which may affect the performance of this method. Therefore, IV injections 
have to be monitored and any failed attempts noted, in order to rule out the injection 
as a source or variation. 
 
Secondly, the ultrasound application to an organ of interest is subject to 
handler variations. The transducer will be placed over the region of interest with the 
help of the imaging screen of the scanner and will then have to be swept over the 
organ to achieve optimal coverage of the entire organ. The imaging screen will be 
used to guide the transducer to the correct region of interests and will help to 
minimise variation during scanning. 
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Finally, it must to be taken into consideration that the ultrasound beam is 
attenutated by tissue and bones. This depth-deependend attenuation can contribute to 
variations in ultrasound intensities that the target organ is exposed to. 
 
3.2 Bioluminescence Imaging using Xenogen IVIS 100 
 
3.2.1 Background – In vivo bioluminescence imaging 
 
In vivo bioluminescence imaging is a non-invasive method to measure 
luciferase expression in animals. The luciferase reporter gene is very popular for in 
vivo studies, primarily because in vivo bioluminescence imaging is fast, sensitive and 
free of false positives150. Firefly Luciferase, a 62,000 Dalton protein, is only active in 
the presence of its substrate, D-Luciferin, and its co-factors. Luciferase catalyses the 
ATP-dependent D-luciferin oxidation into oxyluciferin with emission of 
bioluminescent light centered at 560nm (Fig.3.6A). The reaction follows Michaelis-
Menten kinetics and therefore requires excess amounts of substrate and co-factors to 
achieve maximum light output. And only when assayed under these conditions is the 
light emitted directly proportional to the number of luciferase enzyme molecules. 
Here we use an IVIS Imaging System 100 Series (Xenogen, California, USA) with a 
cooled, charge-coupled device (CCD) camera to visualize areas of bioluminescence. 
This camera localizes and quantifies photons emitted by the luciferase -catalyzed 
reaction in vivo (Fig.3.6B). In vivo bioluminescence imaging has been used to study a 
wide variety of molecular processes such as the proliferation of tumour cells151, 
engraftment of transplanted hematopoietic stem cells152, 153, measurement of tissue 
regeneration154, 155 and to detect protein-protein interactions150. 
 
One of the most important features of using in vivo bioluminescence imaging 
is that there is no need for tissue harvesting. Bioluminescence can be detected and 
quantified in vivo by using Living Image Software (Xenogen, USA) coupled to the 
IVIS 100 camera. Therefore, the same animals can be analysed over a time course, 
which reduces the total number of animals needed.  
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When bioluminescence images are produced by Living Image Software, it has 
to be noted that the software automatically adjusts the intensity levels displayed in the 
image according to the expression levels present in order to produce the best image. 
This however means that if bioluminescence present is only marginally more intense 
than the background, it will also display the background. Also, if very strong levels of 
bioluminescence are present, it will neglect to show any weaker signals, if any are 
present. This has to be taken into consideration when bioluminescence images are 
analysed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6: (A) Reaction catalysed by luciferase. Luciferin combines with adenosine 
triphosphate (ATP), to form luciferyl adenylate and pyrophosphate (PPi) on the 
surface of the luciferase enzyme. The luciferyl adenylate remains bound to the 
enzyme combines with oxygen to form oxyluciferin and adenosine monophosphate 
(AMP). Light is given off and the oxyluciferin and AMP are released from the 
enzyme's surface. (B) Photograph of the Xenogen IVIS 100 in vivo bioluminescence 
camera. 
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3.2.2 Development of a cardiac muscle specific luciferase plasmid 
 
For bioluminescence studies in the heart, a cardiac specific expression cassette 
was needed to eliminate non-specific expression in the liver that can occur when 
microbubbles and DNA are delivered IV with a ubiquitous expression promoter.  
pEGFPluc is a commercially available co-transfection plasmid (BD biosciences) that 
encodes a fusion of enhanced green fluorescent protein (EGFP) and luciferase and is 
driven by a ubiquitous CMV promoter (Fig. 3.7). 
 
Figure 3.7: pEGFPluc plasmid map (taken from www.bdbiosciences.com) 
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For the delivery into heart, a new plasmid (JAC1) was cloned containing a 
cardiac specific promoter (α-MHC) and a GFP/Luciferase fusion protein. The 
GFP/luciferase fusion protein was cut out of pEGFPluc and inserted into an open 
plasmid backbone containing the α-MHC promoter (Fig.3.8, 3.9A). Successful clones 
were identified by size comparison on a 1% agarose gel (section 2.5) of plasmid 
fragments after a triple enzyme digest (Fig.3.9B). The presence of a heavier band 
(3200pb) instead of the smaller one (750bp) seen from the native plasmid, shows that 
the fragment was successfully integrated. Moreover, the presence of a third band for 
triple cuts of ligation products indicates that the SalI site is still intact after ligation, 
suggesting that the reporter gene fragment ligated into α-MHC Clone 26 in the 
correct orientation. Ligation product 4 seems to have the insert integrated in the 
wrong orientation, hence the SalI site is no longer present, and only two fragments 
appear (Fig. 3.9B). PCR of the GFP fragment also confirmed that the reporter gene 
fragments was successfully cloned into α-MHC Clone 26 (see Appendix Fig. 9.1). 
JAC1 plasmid was then used for preliminary in vivo experiments targeting the heart. 
Injection of 200µg JAC1 plasmid together with MBUS targeting the heart showed 
successful luciferase expression in the heart, confirming that the newly cloned 
plasmid JAC1 was functional. 
 
In order to amplify plasmids, they were transformed into competent cells (section 2.4) 
and then purified using Qiagen Giga Prep Kits according to manufacturers 
instructions. 
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Figure 3.8: Steps involved in cloning of JAC1. Plasmid α-MHC Clone 26 (blue) 
(kindly provided by Michael Gollob, University of Ottowa) was used as the main 
backbone for the new JAC1 plasmid. The EGFPluc gene was cut out of a 
commercially available pEGFPluc plasmid (red) and inserted into the open α-MHC 
Clone 26 backbone. Arrows indicate enzyme restriction sites. 
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Figure 3.9: Gel electrophoresis of (A) double cut plasmid pEGFPluc (lanes 1 & 2) 
and double cut plasmid α-MHC Clone 26 (lane 4 & 5). Lane 3 shows 1kb Ladder. (B) 
Triple cut α-MHC Clone 26 plasmid (lane 2), triple cuts of ligation products 1-4 
(lanes 3-6). Lane 1 shows 1kb Ladder. 
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3.2.3 Linear dynamic range and reproducibility of luciferase expression 
 
In order to use in vivo bioluminescence imaging as a means to investigate and 
quantify gene expression, it is important to establish that a linear relationship exists 
between DNA expression and the bioluminescent light output. By demonstrating 
linearity between these two factors, this method can be reliably used as a way of 
quantifying gene expression, and ultimately, in this case, the effectiveness of different 
gene delivery methods. The relationship between increasing doses of plasmid DNA 
encoding the luciferase reporter gene (1-10µg pEGFPluc) injected intramuscularly 
(IM) was tested by measuring bioluminescence expression in vivo (section 2.9). 
Furthermore, the reproducibility of in vivo bioluminescence imaging was investigated 
by imaging several mice injected with the same amount of plasmid.  For these tests it 
was assumed that the relationship between plasmid injected and plasmid expression is 
linear.  
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Figure 3.10: Correlation between bioluminescence and pEGFPluc concentration. 
Duplicate mice were dosed injected intramuscularly with pEGFPluc in the amounts 
indicated. Inset images are representative of mice injected with 1µg and 10µg of 
pEGFPluc as indicated by the dashed arrows (n=5). Line of best fit was generated by 
regression analysis and an R2 value of 0.956 was achieved.  
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Figure 3.11: In vivo bioluminescence detected after IM injections with 5 and 10µg 
pEGFPluc. Error bars represent standard error of the mean (n=4). 
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Figure 3.10 showed the IM injections of increasing amounts of plasmid 
(pEGFPluc) and the corresponding bioluminescence output. This data clearly 
demonstrated a linear relationship between plasmid concentration and bioluminescent 
output. Reproducibility of the linear relationship between bioluminescence and 
plasmid concentration was demonstrated using repeat injections at 5 and 10µg of 
pEGFPluc (Fig. 3.11). Bioluminescence output at 10µg was approximately twice that 
observed for 5µg. This data showed that the linearity demonstrated earlier was 
reproducible. 
 
Sources of variations that could have contributed here were human errors in 
form of a suboptimal injection (either of the plasmid or the luciferin substrate). Other 
factors that generally can contribute may be differences in the tissue expressing 
luciferase, light-scattering effects and the biodistribution of luciferin in mice150. 
Therefore, it is important to show the reproducibility of the results using Standard 
error/deviation and to use the appropriate negative controls for the delivery methods 
under investigation. 
 
 
3.2.4 Effect of substrate concentration on luciferase activity 
 
The substrate, Luciferin, has to be carefully dosed, as the substrate has the 
potential to limit the levels of bioluminescence that can be detected156. With every 
bioluminescence evaluation, a time response curve has to be made to show that stable 
enzyme turnover is achieved and that the substrate is not the limiting factor. Figure 
3.12 shows examples of stable enzyme turnover (□) and expression not achieving 
stable turnover (♦) after IM injections (Fig. 3.12A) and IV injections (Fig. 3.12B). At 
levels of very high luciferase expression, the substrate may be the limiting factor, as 
above 30mg/mL Luciferin is no longer soluble in PBS. In this case, the best reading 
has to be taken, even if no stable enzyme turnover was achieved. 
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3.2.5 Variations in Bioluminescence readings 
 
In order to exclude that variations in readings are due to the camera itself 
rather than a biological reason, the camera was tested using a Xenogen XLS-4 
Calibrated Light Source (section 2.8). Stable readings of the calibrated light source 
allow the assumption that variations in any bioluminescence readings are due to the 
subject and not the camera. 
 
After readings were taken on a day to day and long term basis, it was evident 
that the camera measurements never deviated significantly from the predetermined 
values. According to the manufacturer’s instruction, measured values must not fall 
outside +/-10% of the calibrated value (3.2×108 photons/sec), and must not fall 
outside +/- 3% of the day’s average. All measurements were within these limitations 
(only an example of the data is shown). Within one week of the readings, the highest 
variation form the calibrated value was 0.9%. The maximum variation was seen after 
7 month with 3.4% of the calibrated value. 
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Figure 3.12: Bioluminescence expression over time in (A) tibialis anterior in mice 
after IM injection of 10 and 20µg pEGFPluc and (B) in the liver of two mice after IV 
injection of 250µg pEGFPluc and MBUS treatment. 
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Figure 3.13: Bioluminescence measurement of Xenogen XLS4 Calibrated Light 
source. (A) Measurements taken on day 1, 2, 3, 4 and 7 for 20min. Red lines show + 
and – 10% of the calibrated value (3.2x108 photons/sec). (B) Measurements taken on 
day 2. Red lines show + and – 3% of the days average measurement.  
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Figure 3.14: Bioluminescence measurement of Xenogen XLS4 Calibrated Light 
source. (A) Average measurements of days 1-7. Red lines show + and – 10% of the 
calibrated value. (B) Average measurements from months 0-7. Red lines show + and 
– 10% of the calibrated value. 
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 In order to test if the bioluminescence camera can accurately detect the same 
in vivo bioluminescence output repeatedly, TAs of 3 mice were injected with 5µg 
pEGFPluc. 5 days after injection bioluminescence was measured in the morning and 
in the afternoon of the same day. The reason for taking the measurements so close 
together is that there will only be a minimal variation in the luciferase expressed in 
the muscle fibres. Therefore, variation in the luciferase level can be neglected for this 
comparison. The calibrated light source was also measured during these two time 
points to be able to rule out any variations in camera function. 
 
 Results of the repeated measurements show that there is only a minimum of 
variation between each leg analysed when morning and afternoon values are 
compared (Fig. 3.15). The small variations seen are unlikely to be due to variations in 
the camera, as the values detected for the calibrated light source were stable. 
Variations seen when morning and afternoon readings were compared, are most 
likely due to differences in the biodistribution of the luciferin caused by small 
variations in IP injections. Variations seen between the readings of the six legs were 
most likely due to variations in the intramuscular injection.  
 
Generally, variations in bioluminescence measurements are most likely due to 
problems described in Section 3.2.3, such as problems with the injection of the 
plasmid or Luciferin (human error), problems with the biodistribution of Luciferin or 
the limitations of Luciferin concentration available. Because of these possible sources 
of error, experimental controls and statistical analysis are necessary to ensure the 
validity of all results. 
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Figure 3.15: Bioluminescence measurement of Tibialis Anterior of three C57BL10 
mice 5 days after single injection of 5µg pEGFPluc. Measurements were taken twice 
on the same day, once is the morning, once in the afternoon. Xenogen Calibrated 
lights source was measured immediately after in vivo measurements were taken to 
show stability of camera measurements. 1, 2: left and right TA of mouse #1. 3, 4: left 
and right TA of mouse #2. 5, 6: left and right TA of mouse #3. Cal light: calibrated 
light source.  
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3.2.6 Summary 
 
In this chapter the use of diagnostic ultrasound as well as bioluminescence 
imaging as laboratory tools were discussed and their functions were evaluated. Both 
modalities play an important role in the experiments discussed in this thesis, therefore 
their accuracy and potential sources of variations were investigated.  
 
In order to determine the default ultrasound settings for the investigation of 
diagnostic ultrasound for gene delivery, the ability of the ultrasound scanner and its 
transducers were considered and experimentally validated. The 15L8 transducer was 
chosen due to its size for most even scanning of the organs of interest and for best 
imaging resolution.  In order to have the best chance of achieving inertial cavitation 
with this transducer, frequency and MI will be set according to the Acuson Sequoia to 
a frequency of H14MHz and MI 1.8. Experimental validation of these parameters 
have shown that these settings effectively correspond to a transmission frequency of 
5.9MHz and an MI of 0.71 (P-=1.73MPa). The duty cycle at which this setting 
operates has been determined to be 0.021%. This duty cycle is substantially lower 
than duty cycles commonly used with therapeutic ultrasound settings and therefore, 
diagnostic ultrasound should be safer to apply. 
 
In vivo bioluminescence imaging is a valuable technique for rapid and 
accurate analysis of luciferase reporter gene expression. Advantages such as the 
ability to repeatedly image the same mouse and the fast data output made luciferase 
the optimum reporter gene system for the investigation into the use of MBUS for 
gene delivery. It was established that bioluminescence imaging is reproducible and 
has a linear dynamic range, which allows this technique to be used as a reliable way 
of quantifying gene expression. Moreover, it was shown that the camera itself 
functions accurately and therefore the camera can be ruled out as a source of variation 
in bioluminescence measurements. The main sources of variations that have to be 
taken into consideration are variations of injections, both of plasmid and Luciferin. 
Therefore, experimental controls and statistical analysis will be necessary. 
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4 Proof of concept 
 
4.1 Introduction 
 
In the last decade, considerable effort has been invested into establishing safe 
and effective gene therapy approaches. In Chapter 1, the pros and cons for viral and 
non-viral gene therapies were discussed and the main chemical and physical 
enhancers currently under investigation were introduced. Enhancers for non-viral 
gene therapy are necessary as naked DNA is not as efficient as viral vectors for gene 
therapy. However, non-viral methods are regarded as the safer approach, as so far, 
problems with immunotoxicity and integration of viral vectors have not been 
overcome. Therefore, enhancers for non-viral gene therapy have generated much 
interest. Currently, physical enhancers seem to have more success compared to 
chemical enhancers, however both avenues are still under investigation. The most 
popular and efficient physical enhancers are the gene gun and electroporation. While 
both have been successful in the clinic, there are still some issues that need to be 
addressed. The gene gun approach has only been shown to be effective for shallow 
targets, while electroporation has only shown potential in combination with direct 
injections of plasmid, which can cause tissue damage to the target area. Finally, 
placing the electrodes onto the target organ when using electroporation can be an 
invasive technique.  
 
 
There is therefore a clear need to improve enhancers for gene therapy to 
achieve a safe, efficient and practical system to target the gene of interest to a specific 
target tissue. In this chapter, the feasibility of diagnostic ultrasound in combination 
with microbubbles as a physical enhancer for gene therapy is investigated. 
Microbubble ultrasound (MBUS) treatment will be tested together with a systemic 
administration of plasmid DNA and the ability of this system to target different types 
of tissue will be investigated. 
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4.2 Results 
 
4.2.1 MBUS improved gene delivery to the liver 
 
 
In order to investigate if MBUS could improve the delivery of a reporter gene 
to the liver, pEGFPluc plasmid was mixed with the microbubble (MB) Optison 
(~1.2×108 bubbles) in a volume of 200µL and injected intravenously (IV) into the tail 
vein of C57BL10 mice. Once the solution was injected, ultrasound (US) was applied 
to the liver for 2 minutes using the 15L8 transducer of the Siemens Acuson Sequoia 
on a H14MHz, MI 1.8 setting (Fig. 4.1). Control mice received injections with either 
plasmid alone or plasmid with MB or US only. In order to ensure optimal ultrasound 
penetration with as little attenuation as possible, the fur was removed from the 
abdominal area (section 2.7). 
 
7 days after injections with MBUS treatment of the liver, mice were analysed 
using the Xenogen IVIS 100 in vivo bioluminescence camera (section 2.9). For 
analysis, mice were injected interperitoneally with 300mg/kg luciferin before they 
were anaesthetised using isoflurane gas anaesthesia. Once all mice were down, they 
were moved into the camera chamber, where images were captured with an exposure 
time of 5 minutes for 40 minutes. In order to establish bioluminescence intensity 
resulting from luciferase activity in the liver, a region of interest (ROI) was drawn 
around the liver, and photon flux was measured within this region. The final reading 
of bioluminescence intensity was taken from an area of maximum enzyme turnover 
established from the time curve. The ROI was constant for all livers evaluated. GFP 
expression was not analysed here, as the positive controls (direct intramuscular 
injections of pEGFPluc) did not show detectable levels of GFP, possibly as a result of 
the fusion to luciferase. Therefore, GFP was not expected to be detectable after this 
treatment. 
 
Images and intensity readings taken of treated mice and controls on day 7 
showed that the combination of MBs and US was required in order to observe a 
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significant improvement in gene delivery (Fig. 4.2 C&D). MBUS treatment of the 
liver allowed a 40-60 fold increase in luciferase expression compared to injections 
with plasmid alone. Treatment with MBs or US alone showed no significant 
improvement (Fig. 4.2 A, B&D). Injections with three different concentrations of 
pEGFPluc (total amount injected was 100µg, 150µg and 250µg) showed that in each 
case, MBUS lead to a significant improvement in gene delivery (P<0.0004, 
P<0.0002, P<0.0003, respectively). A dose dependence on the concentration of 
plasmid injected was seen, which showed that the optimum plasmid concentration 
will have to be established for each plasmid type used with MBUS, in order to use it 
to its full potential. 
 
As the plasmid was injected IV, other organs and tissues were analysed ex 
vivo for luciferase expression with the bioluminescence camera in order to establish if 
the plasmid was taken up by any other tissue other than the liver. Bioluminescence 
imaging showed no detectable luciferase expression in any of the organs and tissues 
analysed, except for the MBUS treated liver. This included kidneys, spleen, heart, 
lung, intercostal muscle, skeletal muscle from leg and liver adjacent skin and 
abdominal muscle (Fig. 4.3).  
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Figure 4.1: (A) Picture of mouse under anaesthesia being given ultrasound to the 
liver with a 15L8 transducer (Siemens Acuson Sequoia). (B) Ultrasound image of 
mouse liver 30 seconds after IV injection of Optison.  
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Figure 4.2: In vivo bioluminescence imaging of mice (ventral) at day 7 after IV 
injection of pEGFPluc (250µg) (A) plasmid only, (B) plasmid with MBs, (C) plasmid 
with MBs and 2 minutes US to the liver. Colours represent intensity values given on 
scale bar. (D) Average photon flux resulting from luciferase activity in mouse liver 
on day 7 after injection of 100µg, 150µg and 250µg of pEGFPluc with or without 
MBs and US (*P<0.0004, **P<0.0002, ***P<0.0003, n=5). 
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Figure 4.3: (A) Ex vivo bioluminescence imaging of mouse organs and tissues at day 
7 after IV injection of 150µg pEGFPluc with Optison and 2 minutes US to the liver. 
Colours represent intensity values given on scale bar. (B) Organs and tissues seen in 
A. 
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4.2.2 Long term luciferase expression in liver treated with MBUS 
 
Gene expression that is induced by non-viral vectors such as plasmids has the 
disadvantage that it will decline over time due to lack of integration into the genome. 
To investigate the decline of luciferase expression in this approach for non-viral gene 
therapy, luciferase expression in the liver was analysed 3 months after plasmid 
injection with MBUS (Fig. 4.4). Although luciferase expression was still detectable 
after 3 month in mice injected with 250µg of plasmid, the drop in luciferase 
expression was significant (P<0.001). Therefore, it is important that the treatment 
procedure for non-viral gene therapy is practical and safe, so that repeated or even 
regular treatments are possible, which would allow to keep up levels of gene 
expression over time. To analyse if MBUS caused any damage to the liver, liver 
samples were taken 24 hours after MBUS treatment, sectioned and stained with 
Haemotoxilin and Eosin (H&E) for histological analysis (section 2.12). If any 
damage occurred, an influx of nucleated cells should be visible on H&E stained 
sections. All H&E liver sections analysed showed no signs of tissue damage and 
general cell morphology was indistinguishable from untreated control sections (Fig. 
4.5). 
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Figure 4.4: Average photon flux resulting from luciferase activity in mouse liver 7 
days  and 3 month after injection of 250µg pEGFPluc with MBs and 2 minute US 
exposure to the liver (P< 0.001, n=5). 
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Figure 4.5: Microscope images of liver sections stained with H&E. (A-B) Liver 
sections from untreated C57BL10 mice. (C-D) liver sections from mice taken 24 
hours after MBUS treatment of the liver. Scale bar represents 200µm. 
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4.2.3 Moving gene expression from the liver to the heart 
 
In section 4.2.1 it was shown that when pEGFPluc was injected IV with MBs 
and US applied to the liver, luciferase expression was significantly improved. One of 
the advantages of using diagnostic ultrasound for MBUS, is that an image of the 
scanned area is displayed, which allows for a very precise application of the 
ultrasound to the organ of interest. In order to investigate if the expression of 
luciferase could be moved from one organ to another, just by moving the ultrasound 
exposure, the transducer was moved from the liver to the heart. pEGFPluc carries 
luciferase under a ubiquitous CMV promoter, which allows luciferase to be expressed 
in any tissue type. Therefore, pEGFPluc was injected IV with MBs, exactly as for the 
previous liver experiments, however, now the ultrasound exposure was targeted to the 
heart. US was applied with the 15L8 transducer with a H14MHz, MI 1.8 setting for 2 
minutes (Fig. 4.6) once the MBs appeared in the heart (Fig. 4.7A). US imaging in 
CPS mode, a MB sensitive mode, showed that MBs were not only present in the 
cavities of the heart, but also in the microvasculature of the myocardium (Fig.4 7B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.6: Picture of mouse under anaesthesia being given ultrasound to the heart 
with a 15L8 transducer (Siemens Acuson Sequoia). 
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Figure 4.7: Ultrasound image of mouse heart 1 minute and 39 seconds after IV 
injection of Optison in (A) harmonics mode with a H14MHz MI1.8 setting and (B) in 
CPS mode (14MHz, MI 0.24). Arrow indicates microbubbles in myocardium. (C) 
Ultrasound image of mouse heart in CPS mode (14MHz, MI 0.24) before injection of 
microbubbles. 
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In vivo bioluminescence imaging 7 days after MBUS treatment showed luciferase 
expression in the area of the heart, without any detectable expression in the liver (Fig. 
4.8). It appears as if a little bioluminescence expression is present in the front right 
foot of the mouse (Fig. 4.8), however, this is not caused by luciferase activity, but can 
be attributed to bioluminescent light from the heart being reflected off the foot. Ex 
vivo analysis however, showed that luciferase expression was not only present in the 
heart, but also in thoracic tissue which was also exposed to the ultrasound beam (Fig. 
4.9A). Moreover, the intensity of luciferase expression in the thoracic tissue was very 
strong, which masked any luciferase expression that might have been present in the 
heart. When the heart was imaged on its own, luciferase expression could be detected 
in the heart (Fig. 4.9C). When the liver was imaged in the absence of the thoracic 
tissue and the heart, to rule out that the expression in the liver was masked by other 
luciferase expression present, no luciferase activity was detected (see Appendix 
Fig.9.2). This confirmed that MBUS could be used to move gene expression from one 
organ to another, just by re-directing the ultrasound beam. However, it is unavoidable 
that the ultrasound beam passes through thoracic tissue when the heart is targeted. 
Therefore, the tissue specificity would need to be improved in order to avoid 
expression in thoracic tissue. 
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Figure 4.8: In vivo bioluminescence imaging of mouse (ventral) at day 7 after IV 
injection of pEGFPluc (200µg) with MBs and 2 minutes US to the heart. Colours 
represent intensity values given on scale bar. 
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Figure 4.9: Ex vivo bioluminescence imaging of (A) mouse organs and tissues and 
(C) heart only at day 7 after IV injection of 200µg pEGFPluc with MBs and 2 
minutes US to the heart. Colours represent intensity values given on scale bar. (B) 
Organs and tissues seen in A. 
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4.2.4 Improving on specificity of gene expression in myocardium 
 
  In order to improve the specificity of gene expression in the heart, a new 
plasmid was cloned that carried luciferase under a cardiac specific promoter. The 
gene for the fusion of enhanced green fluorescent protein (EGFP) and luciferase was 
taken from pEGFPluc which was cloned into a plasmid cassette containing the 
promoter for αMHCI (section 3.2.2). The new plasmid was called JAC1. JAC1 was 
used to repeat the experiments described in section 4.2.3. 200µg JAC1 were injected 
together with Optison (~1.2×108 bubbles) IV into 5 week old C57BL10 mice and a 2 
minute ultrasound exposure (H14MHz, MI 1.8) was applied to the heart, once the 
injection was given. Again, in vivo bioluminescence imaging showed luciferase 
expression in the area of the heart (Fig. 4.10A). Ex vivo analysis of the heart and 
thoracic tissue showed that luciferase expression was present in the heart only (Fig. 
4.10C). The cardiac specific promoter of JAC1 successfully prevented luciferase 
expression in thoracic tissue. 
  
 
 Bioluminescence imaging was used to quantify luciferase activity on day 7, 
which was used for statistical analysis. Results showed that luciferase activity in the 
heart was increased 20-fold (P<0.02) when gene delivery was aided by MBUS (Fig. 
4.11). In order to ensure that no damage was caused by the MBUS treatment, hearts 
of treated mice were taken 24hrs after injections with MBUS for histological 
analysis. H&E stained sections of treated mice showed no morphological differences 
to untreated hearts (Fig. 4.12). This demonstrated that MBUS is able to improve gene 
delivery safely, independent of tissue type. 
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Figure 4.10: In vivo bioluminescence imaging of mouse 7 days after JAC1 injection 
(200µg) with (A) MBS and 2 minute US to the heart and (B) without MBUS. (C) Ex 
vivo bioluminescence imaging of mouse heart and thoracic tissue at day 7 after IV 
injection of 200µg pEGFPluc with MBs and 2minutes US to the heart. Colours 
represent intensity values given on scale bar.  
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Figure 4.11: Average photon flux resulting from luciferase activity in mouse heart 7 
days after injection of 200µg JAC1 with and without MBUS treatment of the heart 
(*P<0.02 controls: n=4, treated: n=6) 
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Figure 4.12: Microscope images of heart sections stained with H&E. (A) Heart 
section from untreated C57BL10 mice. (B) Heart section from mice taken 24 hours 
after MBUS treatment of the liver. Scale bar represents 200µm. 
A 
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4.3 Discussion 
 
 In this chapter, the results show that the application of MBUS was successful 
in improving reporter gene expression in the liver as well as the heart following an 
intravenous injection of non-viral plasmid. Experimental controls with MB alone and 
even with US alone did not achieve better gene expression compared to injections 
with plasmid alone. The luciferase activity detected for injections with plasmid only 
and MBs or US only was most like due to Kupffer cells taking up plasmid by 
phogocytosis, rather than active gene delivery. The intensity of the diagnostic US 
wave alone was not enough to cause a sonoporation effect which could have lead to 
improved gene delivery. Only in combination with MBs did diagnostic US 
successfully enhance gene delivery. Moreover, it was shown that changing the 
application from liver to heart was simple, as it only required the re-direction of the 
ultrasound transducer. Directing the transducer correctly was aided by the imaging 
capability of the ultrasound scanner, which not only allowed precise targeting of the 
US beam, but also showed microbubbles appearing in the organ imaged. 
 
When MBUS was applied to the liver, no detectable reporter gene expression 
was observed in any other organ but the liver, even though the reporter plasmid was 
injected intravenously. The low plasmid concentration injected reduced the 
possibility of non-specific cellular uptake in other tissue. This shows that MBUS 
allows gene therapy with concentrations that are too low for detectable non-specific 
cellular uptake, which are however sufficient to result in gene expression in the 
MBUS treated tissue.  
 
When MBUS was applied to the heart with the reporter plasmid carrying a 
ubiquitous CMV promoter, luciferase expression was detected in the heart as well as 
in the intercostal muscle adjacent to the heart. No luciferase expression was detected 
in liver. Although in Fig. 4.2B it was shown that when 250µg of plasmid were 
injected together with Optison alone, some expression was detected in liver. 
Therefore, it is possible that when more than 200µg plasmid is injected for MBUS 
treatment of the heart, there would be some background expression in the liver.  
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The strongest luciferase activity after injection of pEGFPluc and MBUS to the 
heart was seen in the intercostal muscles adjacent to the heart. Although these 
muscles were not the target, they did receive MBUS treatment when ultrasound was 
applied to the heart. While scanning the heart, the transducer is placed onto the 
ribcage (Fig. 4.6). Furthermore, intercostal muscles are well perfused with blood, and 
therefore with microbubbles, even when the mouse is under anaesthesia. Therefore, 
the intercostal muscles adjacent the heart also received MBUS treatment, although 
unwanted. As there was no alternative way to place the transducer while scanning the 
heart, the background in the intercostals was eliminated by using a plasmid that 
carried the reporter gene under a cardiac specific promoter (αMHCI). It has to be 
noted however that the unwanted background seen in the intercostal muscles 
suggested that skeletal muscle also respond to MBUS. This was investigated further 
in a later chapter. 
 
 When MBUS treated hearts were imaged ex vivo, only very little 
bioluminescence was detected. One of the requirements for bioluminescence activity 
is the presence of co-factors for luciferase. One of these co-factors is ATP (section 
3.2.1). It is possible that the heart very rapidly depletes of ATP, more so than the 
liver, because it keeps beating for some time, even after breathing of the mouse has 
ceased. Therefore, it is possible that the ex vivo images of heart are not completely 
representative for the actual intensity and distribution of luciferase activity in the 
heart. 
 
When reporter gene expression was analysed 2 month after MBUS treatment, 
luciferase activity in the liver was significantly decreased. This loss in activity likely 
reflects the loss of the plasmid from cells undergoing mitosis in the liver, as the 
plasmid will not have integrated into the genomic DNA. This emphasizes that gene 
therapy with non-viral vectors requires repeated treatment in order to sustain 
therapeutic levels of the gene product of interest. Therefore it is paramount that the 
treatment approach is easy to administer and safe. The microbubble used in this 
study, Optison, is already licensed for use in patients. Optison is known not to be 
toxic or immunogenic in man and it is rapidly cleared from the body. Therefore, 
Deleted: e
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repeated injections of this microbubble are allowed. The diagnostic ultrasound used 
for MBUS was also within the FDA recommended guidelines (MI 1.8, see section 
1.3). However, the combination of Optison with high MI US was novel and therefore 
histological analysis of liver as well as heart tissue was carried out. 24hrs after 
MBUS treatment, tissue sections showed no signs of tissue damage. This allowed the 
conclusion that any pores caused by MBUS were reversible and cell membranes were 
able to rapidly repair. 
 
 MBUS was shown to improve gene delivery in both the liver and the heart 
and the results in the liver also show that MBUS is dose dependent. Therefore, it is 
possible that increasing the plasmid concentration injected would further improve 
MBUS aided gene delivery. The optimal concentration for gene delivery with MBUS 
will have to be found for each type of therapeutic plasmid used, as different 
promoters, different gene expression levels required and the size of the plasmid can 
influence the plasmid concentration required for best results. 
 
 Differences in expression levels between liver and heart may be due to 
differences in attenuation of the ultrasound beam before it reaches the target.  Bones 
(ribs) over the heart for example, can cause echo shadows and result in weaker 
ultrasound exposure when compared to the liver. 
 
In summary, MBUS was successful in improving gene delivery in liver and 
heart, which allows the conclusion that MBUS can be applied independent of tissue 
type. Moreover, MBUS was shown to be a safe, non-invasive procedure, which 
allowed targeted gene therapy when plasmid DNA was injected intravenously due to 
the precise application of the ultrasound.   
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5 Therapeutic Application of MBUS 
5.1 Introduction 
 
Duchenne muscular dystrophy (DMD) is an X-linked recessive neuromuscular 
disorder caused by mutations in the dystrophin gene that in most cases lead to 
premature termination of translation and consequent lack of functional dystrophin in 
muscle fibres157. Dystrophin, a large multidomain protein, links the actin cytoskeleton 
to the extracellular matrix with its two terminal domains (Fig. 5.1A)158. The amino-
terminus of dystrophin binds to F-actin and the carboxyl terminus to the dystrophin-
associated complex at the sarcolemma159. Connecting them is a central rod domain 
composed of 24 repeating units, which account for the majority of the dystrophin 
protein159. Lack of dystrophin leads to loss of ambulation during or shortly after the 
first decade of life, followed by progressive weakening of muscles, and death usually 
during the early twenties. The mutations responsible for DMD vary widely in terms 
of types of mutations (deletions, duplications, inversions, point mutations) and in 
terms of the locations along the 2.5Mb dystrophin gene160. Mutations that lead to in-
frame deletions producing an internally truncated dystrophin without affecting the 
actin and extracellular matrix binding domains result in a milder myopathy, termed 
Becker muscular dystrophy (BMD)161. Analysis of deletions in BMD has shown that 
the central rod domain of dystrophin can accommodate large in-frame deletions, 
permitting the production of partially functional protein.  In over 92% of DMD 
patients, mutations are within the non-critical, central part of the dystrophin 
molecule162. Therefore, DMD is a possible target for gene correction by antisense 
oligonucleotide (AO) mediated skipping of the exons bearing or flanking the disease 
causing mutations. 
 
AOs targeted to splice sites or splicing regulatory regions of pre-mRNA alter the 
splicing of that transcript, presumably by interfering with the normal splicing 
machinery. Therefore, AO-mediated exon skipping is able to convert out-of frame or 
prematurely terminated transcripts into shortened, but in-frame transcripts, 
independent of the mutations causing the problem (Fig. 5.1B)163. The first evidence 
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of exon skipping in the dystrophin gene was shown by Takeshima et al., who 
achieved skipping of exon 19 in normal human lymphoblostoid cells using 2’O 
methyl oligonucleotides (2’OMe ON)164. Further in vitro proof of concept studies 
were obtained from several groups, showing that 2’OMe ONs as well as 
Phosphorodiamidate Morpholino Oligomers (PMOs) could be efficiently used to 
achieve exon skipping in cultured muscle cells from DMD patients165-169. Dunckley et 
al. first showed exon skipping in cultured primary muscle cells derived from the mdx 
mouse, an animal model for DMD170. The mdx mouse has a nonsense point mutation 
CAA→ TAA (Gln→Stop) at base 3185 in exon 23 of the murine DMD gene171. 
However, the AOs used by this group (2’OMe ONs) targeted to  the 3’ splice site of 
intron 22 were not very efficient, as only very low levels of altered transcript were 
detected170. A more efficient approach was achieved by Wilton et al., who used 
2’OMe ONs to target the 5’ splice site of intron 23172. Using 2’OMe ONs targeted to 
the same site, Lu et al. were the first showing efficient skipping with functional 
improvement in vivo, after intramuscular injections of 2’OMe ONs into the tibialis 
anterior of the mdx mouse122. The success of exon skipping in pre-clinical settings 
has led to the move to preliminary clinical studies in DMD patients. Initial results 
from one of the two ongoing clinical trials have recently been published, showing that 
local administration of 2’OMe ONs targeted to a 20-nucleotide sequence within exon 
51 of the human DMD gene resulted in specific skipping of exon 51. This corrected 
the reading frame in the selected patients and consequently introduced dystrophin in 
the muscles of all patients treated. The dystrophin restoring effect was limited to the 
treated area, and therefore no strength improvement of the muscle was observed. 
Furthermore, injections of 2’OMeONs were not associated with clinically apparent 
adverse events when given intramuscularly173. 
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Figure 5.1: (A) The dystrophin-associated protein complex in muscle linking the 
internal cytoskeleton to the external matrix. NOS: nitric oxide synthase. (Taken from 
Nowak & Davies, 2004). (B) Molecular mechanism of AON-induced exon skipping 
to convert a Duchenne phenotype into a Becker phenotype. The nonsense mutation of 
the mdx mouse is shown as an example (Taken from Rando, 2007). 
A 
B 
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Effective treatment of DMD, however, is only possible if all affected muscles 
throughout the body can be targeted. Thus far, the most successful non-viral systemic 
treatment of the mdx mouse was achieved by intravenous (IV) injection of PMOs 
(Fig. 5.2A)174. At physiological pH, PMOs possess a non-ionic backbone, which 
makes them a better therapeutic alternative to other antisense chemistries. The non-
ionic character avoids potential non-specific interaction with cellular components and 
also shows good resistance to nuclease and protease activity, which results in 
enhanced stability in blood175, 176.  Furthermore, it allows PMOs to be injected in a 
concentration high enough to result in a sufficient tissue concentration177. PMOs have 
been tested in pre-clinical studies and clinical trials and have proven to have an 
excellent safety profile178-180. 
 
IV injections of PMOs into the tail vein of the mdx mouse resulted in uptake of 
PMOS in muscle fibres. PMO uptake was sufficient to be able to achieve and 
maintain therapeutic levels of dystrophin in most muscles throughout the body, with 
the exception of the heart (Fig. 5.2B)174. The same observation was made when a 
canine model of DMD was given IV injections of PMOs. Again, increased levels of 
dystrophin were achieved in most muscle, but not the heart (personal communication 
with T.Yokota). Therefore, it is possible that the same problem would occur if this 
treatment should be applied in humans. The heart is a crucial target for DMD therapy 
as primary dilated cardiomyopathy occurs in patients over the age of 18 leading to 
dangerous arrhythmias and potential heart failure181. Cardiac mortality has recently 
replaced respiratory failure as the leading cause of death due to the widespread use of 
mechanical ventilation182, 183. Therefore there is a need to adapt the delivery of PMOs, 
so that the myocardium as well as all other muscles in the body can be successfully 
treated.  
 
Although i.v. injections of PMOs alone did not introduce dystrophin expression 
in cardiac muscle, Denti’s group did achieve dystrophin expression in heart through 
exon skipping by using an antisense AAV construct. In their study, an antisense-U7 
small nuclear RNA (snRNA) was used as part of an AAV construct to induce exon 
skipping184. The successful use of this antisense AAV construct leads to the 
conclusion that there is a delivery issue with the naked PMOs to the heart, as exon 
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skipping itself does not seem to be the problem in the myocardium. Therefore, the use 
of MBUS as a safe, physical enhancer for the delivery of PMOs into the heart was 
investigated.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: (A) Chemical structure of the phosphorodiamidate morpholino oligomer 
(Taken from Rando, 2007). (B) Western Blot analysis showing induction of 
dystrophin expression. Levels of dystrophin in the treated mdx mouse reached >50% 
of normal levels in gastrocnemius and quadriceps, but no expression was seen in the 
heart. C57TA: Tibialis anterior from C57BL10 mouse, Diaph: diaphragm, Abdom: 
abdominal, TA: Tibialis Anterior, Quad: quadriceps, gas: gastrocnemius (Taken from 
Alter et al., 2006) 
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5.2 Results 
5.2.1 Improved delivery of PMOs to mdx myocardium with MBUS 
 
In order to investigate if MBUS could be successfully applied for the delivery 
of PMOs to a dystrophic heart, mdx mice were injected IV with a combination of 
PMOs (16mg/kg) and Optison (~1.2×108 bubbles) followed by 2 minutes US 
exposure of the heart (section 2.10). 7 days later, hearts were harvested and analysed 
for dystrophin (section 2.11). MBUS treated hearts were compared to untreated mdx 
hearts and appropriate controls (US and PMOs, MB and PMOs and PMOs only). 
Immunohistochemical analysis of mdx myocardium that received PMO injections IV 
without MBUS treatment showed a maximum of 9 dystrophin-positive 
cardiomyocytes per section (Fig. 5.3A and B). Control mdx myocardium treated with 
PMOs in combination with MB or US alone also showed no more than 10 
dystrophin-positive cardiomyocytes (Fig. 5.3A). Mdx myocardium treated with 
MBUS showed large numbers of dystrophin-positive cardiomyocytes throughout the 
heart, with more than 400 positive cardiomyocytes detected per section (Fig.5.3A and 
C). Not only was there a good distribution in the cross-sections, dystrophin-positive 
cardiomyocytes were also well distributed from the base to the apex of the heart. A 
western blot for dystrophin using a protein extract from MBUS treated myocardium 
also showed the presence of dystrophin in the heart after MBUS treatment (Fig. 5.4B, 
section 2.14). To confirm that dystrophin positive cardiomyocytes occur due to exon 
skipping, RT-PCR analysis of the mRNA region of interest was performed as 
previously described (section 2.13) and PCR products were examined by 
electrophoresis on a 1.5% agarose gel (section 2.5). RT-PCR analysis of MBUS 
treated mdx myocardium showed mouse dystrophin mRNA of the size expected for 
deletion of exon 23, together with a product of the size consistent with loss of exon 
22 and 23. No skipped product was observed in control samples (Fig. 5.4A).  
 
  A time course study showed a declining but still substantial number of 
dystrophin positive cardiomyocytes at 1 and 2 months post treatment (Fig. 5.4C). 
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This decline was not unexpected, as this treatment is a modification at the RNA level 
only and does not modify the gene itself.  
 
In order to detect any damage associated with the use of a combination of 
microbubble and ultrasound we compared H&E stained mdx hearts taken 20 hours 
and 7 days after a single treatment to untreated mdx hearts. It must be considered that 
mdx mice have a strong background of dystrophic inflammation, therefore hearts 
were analysed for an increase or decrease in inflammation. Two observers examined 
the slides without prior knowledge of the samples identity and found no difference in 
inflammation (decrease or increase) after MBUS treatment.  
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Figure 5.3: Restoration of dystrophin expression in mdx mouse myocardium. (A) 
Significant (* P< 0.0001) increase in dystrophin-positive cardiomyocytes per section 
of heart of mdx mice treated with MBUS compared to control mdx mice (n=6). (B) 
Immunofluorescence images of myocardium from mdx control mouse and (C) mdx 
treated with a single intravenous injection of PMOs plus MBUS. Sections were 
stained for dystrophin with rabbit polyclonal antibody P7185 and counterstained with 
DAPI to show nuclei. Scale bar indicates 200µm. 
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Figure 5.4: Restoration of dystrophin expression in mdx mouse myocardium. (A) 
RT-PCR of for dystrophin mRNA in myocardium from treated and control mdx mice. 
M: marker lane, 1: untreated mdx myocardium, 2-4: mdx myocardium after one 
intravenous injection with PMOs and MBUS, 5: mdx myocardium after one 
intravenous injection with PMOs and Optison, 6: mdx myocardium after one 
intravenous injection with PMOs and US, 7: mdx myocardium after one intravenous 
injection with PMOs only. Full length dystrophin mRNA and truncated dystrophin 
mRNA missing exon 23 and exon 22-23 are indicated. (B) Western blot analysis 
showing induction of dystrophin expression in heart treated with PMOs and MBUS. 
(C) Reduction of dystrophin-positive cardiomyocytes in mdx heart 1 and 2 months 
after IV PMO injection with MBUS. Dystrophin-positive cardiomyocytes present 2 
months after treatment were still significantly increased compared to untreated heart 
(* P< 0.0002, n=5).  
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Figure 5.5: H&E stains of mdx myocardium (A, B) untreated, (C, D) taken 20 hours 
after MBUS treatment of the myocardium, (E, F) taken 7 days after MBUS treatment 
of the myocardium. Scale bar indicates 200µm. 
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5.2.2 Repeated MBUS treatment leads to accumulation of dystrophin-positive 
cardiomyocytes 
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As shown in the previous section, dystrophin expression induced by exon 
skipping declined over time. Therefore, PMO injection for the treatment of DMD will 
have to be repeatedly administered. Previous work had already established that PMOs 
alone can be safely injected repeatedly, showing accumulation of dystrophin positive 
fibres in muscles of mdx mice174. To investigate if MBUS treatment of the heart 
could be applied repeatedly, mdx mice were injected twice (one week apart) IV with 
PMOs and Optison with US to the myocardium. Hearts of one group of animals were 
harvested 7days after the first injection, hearts of animals in the second group were 
harvested 7 days after the second injection. Hearts were then sectioned and analysed 
for dystrophin expression. 
 
Analysis of myocardium treated twice with PMOs and MBUS showed a 
significant increase in dystrophin-positive cardiomyocytes compared to heart in the 
control group that only received a single injection (Fig. 5.6A). Numbers of 
dystrophin-positive fibres increased more than 2 times with very good distribution 
throughout the myocardium cross-sections (Fig. 5.6B). Although repeated injections 
with MBUS were effective, health problems were observed in mice after the second 
injection due to the chemical properties of Optison. The shell of Optison consists of 
human serum albumin, a protein foreign to the mdx mouse. Therefore, immune 
reactions to Optison were observed. Health problems ranged from reduced body 
temperature and unwillingness to move to death. Although more repeated injection 
would be expected to yield even higher accumulation of dystrophin-positive 
cardiomyocytes, due to the problem with Optison in mice no more than 2 injections 
were tested. 
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Figure 5.6: Expression of dystrophin positive cardiomyocytes in mdx myocardium 
after 2 injections of PMOs with MBUS. (A) Significant increase in dystrophin-
positive cardiomyocytes per section of mdx myocardium when injection was repeated 
compared to one injection alone (*P<0.0293, n=4). (B) Representative cross-section 
of mdx myocardium harvested 7 days after the second injection and stained for 
dystrophin (red). Scale bar represents 500µm. 
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5.2.3 MBUS treatment of the heart does not alter PMO uptake of other muscle 
groups 
 
A crucial part of a successful and sensible treatment for DMD is the ability to 
systemically treat all muscles in the body. Using MBUS as a physical enhancer for 
delivery to the heart requires that PMOs are mixed with Optison prior to injection. To 
rule out the possibility that Optison inhibits PMO uptake in other muscle groups, 
muscle sections from gastrocnemius, quadriceps, intercostals, diaphragm and 
abdominal muscles were taken from animals injected with or without Optison and 
analysed for dystrophin expression.  
 
Analysis of dystrophin positive fibres in various muscle groups after IV 
injections with and without Optison showed that there was no significant difference 
in dystrophin expression, although there was a trend in favour of PMOs injected with 
Optison (Fig. 5.7A). Furthermore, MBUS treatment of the heart did not significantly 
influence PMO uptake and consequent dystrophin expression in the skeletal muscle 
groups analysed (Fig. 5.7B).  Therefore, aiding PMO uptake in the mdx heart with 
MBUS allowed PMOs to be taken up by other muscles as seen before without MBUS 
treatment of the heart, consequently making this treatment truly systemic. 
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Figure 5.7: (A) Influence of Optison on PMO uptake into muscle of the mdx mouse. 
Dystrophin positive fibres in mdx muscle after IV injections of PMOs with and 
without Optison and US applied to heart. gas: gastrocnemius, quad: quadriceps, heart: 
cardiac muscle, interco: intercostal muscle, diaph: diaphragm, abdomen: abdominal 
muscles (no significant differences between with and without Optison groups except 
for the gastrocnemius, *P<0.023, n=6). (B) Influence of MBUS treatment of the heart 
on PMO uptake of muscle of the mdx mouse. Dystrophin positive fibres in mdx 
muscle after IV injection of PMOs with Optison and US to the heart compared to 
injections with PMOs alone. No significant increase was detected, with the exception 
of the heart (n=5). gas: gastrocnemius, quad: quadriceps, heart: cardiac muscle, 
interco: intercostal muscle, diaph: diaphragm, abdomen: abdominal muscles. 
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5.2.4 MBUS treatment of mdx skeletal muscle 
 
 In order to investigate if skeletal muscle responded to MBUS treatment with 
systemic (IV) delivery of PMOs, tibialis anterior muscle (TA) of the mdx mice were 
exposed to 2 minutes US after an IV injection of PMOs with Optison. Only one TA 
per mouse was exposed to US (left and right were varied within the group), the other 
one served as a PMO + Optison control. 
 
Direct MBUS treatment of skeletal muscle was shown to improve PMO 
delivery. TA muscles treated with US for two minutes after an IV injection of 
16mg/kg PMOs with Optison showed a 6 fold increase in dystrophin positive fibres 
(Fig. 5.8A). PMO delivery to skeletal muscle also improved when MBUS to the 
skeletal muscle followed MBUS to the heart, although the increase was not quite 
statistically significant (Fig. 5.8B). In this experiment 50mg/kg PMOs were injected 
with 150µL Optison IV, followed by a 2 minute exposure to the heart. Then the 
transducer was moved to the TA for a further 2 minute exposure. A higher 
concentration of PMOs was used in order to account for some of the PMOs entering 
the heart during the first 2 minutes.  
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Figure 5.8: MBUS treatment of skeletal muscle of the mdx mouse. (A) Significant 
increase (*P< 0.0001, n=6) in dystrophin-positive fibres in mdx tibialis anterior (TA) 
after IV injection of PMOs (16mg/kg) with immediate MBUS treatment of TA. (B) 
Increase (#P<0.09, n=5) in dystrophin-positive fibres in mdx TA after IV injection of 
PMOs (50mg/kg) plus 2 minute MBUS treatment of TA after a 2 minute MBUS 
treatment of the heart. MB: microbubbles (Optison). 
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5.2.5 Testing other treatment parameters 
 
In order to investigate which treatment parameters could be further optimised, 
US exposure time, Optison volume, PMO concentration and the US settings were 
varied.  
 
Does a longer US exposure time lead to more dystrophin expression? 
 
To test if a longer exposure time would be more efficient in delivering PMOs 
to cardiomyocytes, the exposure time of US to the heart was increased from 2 
minutes to 5 minutes. This was the only alteration to the standard injection methods 
described in section 2.10. The hypothesis was that a longer exposure time would 
allow the transient pores formed to stay open longer, which would allow more PMOs 
to enter the targeted cells. 
 
Comparison of numbers of dystrophin positive cardiomyocytes showed no 
significant difference between hearts exposed to US for 2 minutes compared to those 
that received 5 minutes of US exposure (Fig. 5.9). During the 5 minutes scans it was 
observed that most of the microbubbles were cleared from the blood circulation after 
2-3 minutes. Therefore, one explanation for the similar results is that the 
microbubbles clear from the system shortly after 2 minutes and therefore, US alone 
was applied for the further 3 minutes, which was shown to have no effect on its own 
in section 5.2.1.  
 
Another possibility was that US exposure for 5 minutes started to induce some 
damage to the myocardium, which was not confirmed by histological analysis. H&E 
staining showed no tissue damage 24 hours after a 5 minute MBUS treatment (Fig. 
5.10). 
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Figure 5.9: Restoration of dystrophin positive cardiomyocytes in mdx mouse after IV 
injection of PMOs in conjunction with Optison and 2 minutes or 5 minutes US 
exposure to the heart. No significant difference was seen in the numbers of positive 
cardiomyocytes per section of heart when the exposure time was increased to 5 
minutes (n=5). 
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Figure 5.10: H&E stains of C57BL10 myocardium (A) untreated, (B) taken 24 hours 
after MBUS treatment of the myocardium. Scale bar indicated 200µm. 
A 
B 
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Is efficient dystrophin expression dependent on the PMO concentration injected? 
 
In order to investigate the possibility that the efficiency of dystrophin 
induction was dependent on PMO concentration, a variety of concentrations were 
injected IV into mdx mice with Optison, followed by a 2 minutes US exposure of the 
heart. The total volume of PMOs and Optison injected was always equalised to be 
200µL.  
 
 A dose response curve was generated varying the PMO concentration from 
4mg/kg to 100mg/kg, keeping Optison and US parameters constant (Fig. 5.11). At 
lower concentrations, an upwards trend was seen, with a significant increase in 
dystrophin-positive cardiomyocytes when 4mg/kg and 16mg/kg were compared 
(P<0.02). However, an injection with 100mg/kg showed no significant increase in 
dystrophin-positive cardiomyocytes. This suggested that PMO concentration was not 
the limiting factor in this treatment.  
 
 
 128
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.11: Dose response curve showing a significant increase in dystrophin-
positive cardiomyocytes when PMO concentration was increased from 4mg/kg to 
16mg/kg (*P<0.02, n=3 and 6, respectively). No significant increase could be seen 
when PMO concentration was increased from 16mg/kg to 100mg/kg (n=5).  
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Does more Optison improve the delivery of 16mg/kg PMOs? 
 
In order to investigate the hypothesis that more microbubbles would be more 
effective for gene delivery, two different approaches were used. The first approach 
was to manually concentrate Optison by centrifugation (section 2.6) in order to 
achieve a more concentrated solution. All injections in this set of experiments used 
the same vial of Optison, half of which was used for the neat injections and the other 
half of which was concentrated. Both were counted and sized for comparison 
purposes (section 2.15, Fig. 5.12). The concentration of the neat vial of Optison was 
determined to be 7.34×108 bubbles/mL. The concentrated Optison after centrifugation 
from the same vial was determined to be 8.68×108 bubbles/mL, which is an increase 
of 18%. The second approach was to inject a larger volume of neat Optison, and 
compare this to a volume matched control. All injections used 16mg/kg PMOs and a 
2 minute US (H14MHz MI1.8) exposure to the heart. 
 
Concentrating Optison by centrifugation only increased the concentration by 
18% and the size distribution of the concentrate showed a very similar distribution to 
neat Optison (Fig. 5.12). Using concentrated Optison for MBUS showed no 
significant difference compared to the use of neat Optison (Fig. 5.14A, P<0.18). 
However, there was a trend in favour of neat Optison. In order to understand more 
about the differences of neat and concentrated Optison that could have caused this 
trend, the concentration of both solutions was observed over a period of 24 hours.  
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Figure 5.12: Size distribution of neat and concentrated Optison both derived from the 
same vial.  
 
Figure 5.13: Changes in the concentration over time of neat and concentrated 
Optison when kept at 4ºC. Total loss of bubbles for neat Optison 24 hours after 
opening the vial is 21%. Total loss of bubbles for concentrated Optison 24 hours after 
opening/centrifugation is 55%. 
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Figure 5.14: (A) Restoration of dystrophin positive cardiomyocytes in mdx heart 7 
days after injection with 16mg/kg PMOs in combination with 150µL neat Optison (as 
provided by manufacturer, 7.34×108 bubbles/mL) compared to 150µL concentrated 
Optison (by centrifugation, 8.68×108 bubbles/mL), both followed by a 2 minutes US 
exposure to the heart. No significant difference was found between the use of neat 
and concentrated Optison. (B) 150µL Optison plus 150µL Saline (300µL total 
volume) compared to 300µL Optison followed by a 2 minutes US exposure to the 
heart. The increase in Optison volume injected lead to a significant increase in 
numbers of dystrophin-positive cardiomyocytes (P<0.05, n=3). 
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0 hours marks the time point when the vial was opened and the centrifugation 
took place. Both vials of neat and concentrated Optison were opened as little as 
possible during the first 3 hours for injection purposes and kept at 4ºC at all times. As 
microbubbles float upwards when the vial is stationary, microbubbles were 
thoroughly resuspended in their solution by careful agitation before each count. 
Changes in the concentration of neat and concentrated Optison show that neat 
Optison is more stable, only loosing 20% of microbubbles during the first 24 hours 
(Fig. 5.13). Concentrated Optison however decreases by 58% in 24 hours. This 
difference may be due to the centrifugation used to concentrate the bubble solution. 
The pressure of the centrifugation may negatively influence shell stability, which 
would explain the faster decline in bubble concentration as well as the slightly less 
effective performance in PMO delivery.  
 
 The second approach tested asked if a larger amount of Optison would yield 
better numbers of dystrophin-positive cardiomyocytes. Therefore, double the normal 
volume (300µL) was used for MBUS injections. Numbers of dystrophin-positive 
cardiomyocytes significantly increased (P<0.05), doubling numbers seen with volume 
matched controls (150µL Optison + 150µL Saline) (Fig. 5.14B). At this time, the 
conclusion can be drawn that Optison concentration was the limiting factor for 
optimum delivery of PMOs to the heart. More dystrophin restoration due to more 
Optison suggests that a 2 minutes MBUS treatment was not enough to deplete 
16mg/kg PMOs from the blood circulation and that better efficacy could be achieved 
by further optimising PMO to microbubble ratio.  
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In order to investigate if MBUS with 300µL could be further improved by 
injecting a higher concentration of PMOs, mdx mice were injected IV with 300µL 
Optison in combination with either 16mg/kg or 50mg/kg PMOs (total volume 
constant) followed by a 2 minutes ultrasound exposure to the heart. Results showed 
that there was no significant different between the groups (Fig. 5.15). Even when 
300µL Optison was used for treatment, the PMO concentration of 16mg/kg was not 
the limiting factor, therefore increasing the PMO concentration will not lead to an 
increase in dystrophin-positive fibres. From these results it can be concluded that the 
microbubble number injected is an important factor for optimising gene delivery with 
MBUS. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.15: Restoration of dystrophin positive cardiomyocytes. Comparison 
between 16mg/kg and 50mg/kg when injected together with 300µL Optison (total 
volume injected: 350µL) showing no significant difference in the numbers of 
dystrophin-positive cardiomyocytes expressed (n=3).  
0
200
400
600
800
1000
1200
300µl + 16mg/kg 300µl + 50mg/kg
Dy
st
ro
ph
in
 
po
si
tiv
e 
ca
rd
io
m
yo
cy
te
s
 134
Different US settings do not improve PMO delivery into cardiomyocytes 
 
In order to investigate the use of different US parameters, settings had to be 
chosen that represent the full spectrum of powers that can be produced by the 
Siemens Acuson Sequoia ultrasound scanner. Therefore, the mechanical index (MI) 
settings measured experimentally in section 3.1.3 were used to determine which 
settings would be compared. Moreover, in order to investigate settings that have a 
higher measured MI than 0.73 and therefore cause more inertial cavitation, a different 
ultrasound transducer was needed. Therefore, the MIs for the 7V3c transducer were 
measured as described previously (section 2.1) and are summarised in Table 5.1. In 
total, 4 settings were chosen to represent a range from very low to maximum MIs that 
can be produced with the Sequoia. Figure 5.16 gives an overview of the chosen 
settings and the measured MIs. Careful consideration has to be given to the fact that 
two different transducers are used in this experiment (differences were discussed in 
section 3.1.2). 
 
 
 
 
 
Table 5.1: Measurements of ultrasound outputs of 7V3c transducer sending a fixed 
frequency of 5 and 3.5MHz with changing MIs. ƒ: Frequency, P+: peak positive 
pressure, P-: peak negative pressure. 
 
Set ƒ 
(MHz) Set MI 
Peak ƒ 
(MHz) 
Mean ƒ 
(MHz) 
P+ 
(MPa) 
−+
 
P- 
(MPa) 
−+
 
Measured 
MI 
5 0.1 4.8 5 0.06 0 0.06 0 0.03 
5 0.94 4.8 5 0.81 0 0.85 0 0.38 
5 1.9 4.8 5 1.98 0.02 2.08 0.02 0.93 
3.5 0.13 3.8 3.8 0.1 0 0.1 0 0.05 
3.5 0.91 3.8 3.8 0.85 0 0.84 0 0.42 
3.5 1.9 3.8 3.8 2.11 0.02 2.05 0.02 1.03 
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Figure 5.16: US settings chosen for comparing their efficiency in PMO delivery. 
Settings are presented in order of Mechanical Index (MI), which was experimentally 
determined for each setting. Note that settings of H14MHz are produced by 
transducer 15L8, 3.5-5MHz by transducer 7V3c. 
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The hypothesis was that a higher MI would cause more cavitation, and more 
cavitation would lead to better PMO delivery. However, it has to be considered that 
not only the MI was changing, but also the transducer and therefore, the area scanned 
may not receive identical levels of US exposure. 
 
When the 15L8 transducer was used, the efficiency of PMO delivery dropped 
significantly when a lower MI was used for MBUS (Fig. 5.17). The same trend could 
be seen for the 7V3c transducer. A lower MI resulted in lower numbers of dystrophin 
positive cardiomyocytes per section of heart. However, comparing all four settings, 
the numbers of dystrophin positive cardiomyocytes detected did not follow the 
expected trend that a higher MI would lead to a more efficient delivery of PMOs with 
consequently higher numbers of dystrophin-positive cardiomyocytes. An MI of 0.93 
was not as efficient as an MI of 0.71. However, changing from the 15L8 transducer 
for MI 0.71 to the 7V3c transducer for MI 0.93 has to be considered. It is possible 
that other factors, linked to the type of transducer, influenced this result as well as the 
change in MI. 
 
The highest numbers of dystrophin positive cardiomyocytes per section of 
mdx heart were achieved with US settings H14MHz MI 1.8 and 3.5MHz MI 1.9 with 
no significant difference (Fig. 5.17, *P<0.85). Both H14MHz MI 1 and 5MHz MI 1.9 
did not achieve more than 100 dystrophin positive cardiomyocytes per section. 
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Figure 5.17: Restoration of dystrophin positive cardiomyocytes in the mdx heart 
using different US settings (*P<0.85, n=3 for H14MHz MI1, 5MHZ MI 1.9 and 
3.5MHZ MI 1.9, n=6 for H14MHz 1.8). 
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5.3 Discussion 
 
It has been shown here that intravenous injection of PMOs combined with 
MBUS treatment of the heart can successfully induce dystrophin expression, resulting 
in a large number of dystrophin positive cardiomyocytes, with no detectable damage 
to the myocardium. Hearts that did not receive any MBUS treatment, showed hardly 
any dystrophin-positive cardiomyocytes. The few positive cardiomyocytes fibres seen 
were most likely revertant. Revertant muscle fibres are found in the mdx mouse171 
and in at least 50% of DMD patients186, 187 and occur due to a naturally occurring 
splicing mechanism that results in restoration of the open reading frame188. The result 
is an internally truncated dystrophin protein,  part of which is encoded by RNA 
sequences downstream from the mutations189, 190. Antisense oligonucleotide induced 
exon skipping mimics this naturally occurring exon skipping event in order to 
produce a large number of these truncated dystrophin molecules, which, if functional, 
would be expected to improve the severity of a DMD phenotype to a milder Becker 
phenotype. An investigation by Alter et al. in the mdx mouse showed that a truncated 
version of dystrophin induced by exon skipping led to a functional improvement in 
the tibialis anterior. An early clinical trial has been successful in producing 
dystrophin by exon skipping, however the levels tested so far, as well as the localised 
nature of the treatment, did not allow the observation of any functional 
improvements173. Functional tests in MBUS treated mdx hearts have thus far not been 
carried out, however future experiments should investigate the function of untreated 
and MBUS treated hearts compared to wile type hearts, potentially by MRI 
measuring right ventricular ejection fractions or right ventricular volumes191 or by 
catheter measuring pressure-volume loops192, 193. However, a functional improvement 
is not expected after just a single treatment with MBUS. At least 20% of 
cardiomyocytes will have to be restored before a functional improvement is expected. 
Therefore, repeated treatments (at least 3-4) will have to be carried out before a 
clinically significant improvement can be expected. 
 
High levels of dystrophin-positive cardiomyocytes in the mdx heart were 
achieved with an MBUS approach using diagnostic ultrasound and a commercially 
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available microbubble, Optison. Using a diagnostic ultrasound system for this 
treatment has the advantage that it is currently available for use in clinical practice 
and furthermore, it gives the opportunity to image the heart during treatment, 
allowing treatment to be targeted in a highly specific manner. Moreover, the use of 
antisense oligonucleotides (PMOs) has been tested for clinical applications. PMOs 
show low toxicity and have thus far not been implicated in any immunological 
reactions. A further advantage of this technique is that exon skipping induced by 
PMOs occurs at the RNA level, without any modifications to the gene itself. This has 
certain advantages over methods that modify at the DNA level (e.g. no risk of 
insertional mutagenesis), PMO treatment may be less efficient as any dystrophin 
expression induced by PMO treatment will be transient in nature. As such, in order to 
be effective, PMO treatment needs to be carried out repeatedly in conjunction with 
MBUS, therefore the safety of this technique is paramount to its success. Histological 
analysis of heart sections taken 7 days after MBUS treatment showed no change in 
inflammation present, which suggests that the truncated dystrophin protein produced 
does not cause an immune reaction. This is likely due to the fact that revertant fibres 
are already present in the untreated mdx mouse, which are almost identical to the 
dystrophin product expressed due to PMO induced exon skipping. Moreover, no 
adverse effects were observed in heart sections taken 24 hours after MBUS treatment, 
which shows that MBUS does not cause irreversible damage to cell membranes. It 
should be noted that no improvement in inflammation was observed, which suggests 
that a single treatment with MBUS does not improve dystrophic inflammation. The 
repeated treatment of mdx heart has shown that two consecutive injections with 
MBUS resulted in the accumulation of dystrophin-positive cardiomyocytes, showing 
approximately double the dystrophin-positive fibres compared to a single treatment. 
However, the use of Optison did result in some adverse affects when injected 
repeatedly into mice. The adverse effects seen were most likely caused by an 
immunological reaction to a foreign protein, in this case Human serum albumin 
(HSA). Therefore, no more than two injections were given, but further improvement 
would be expected with repeated treatments. In a clinical situation the adverse effect 
observed in mice would not be expected in patients, as Optison has been cleared for 
repeated injected into humans (for use with diagnostic ultrasound imaging and this 
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has been done without problems, personal communication with Prof David Cosgrove 
and Dr James Yeh).  
 
While treatment of the heart is of great importance, to be considered useful 
any treatment for DMD has to treat all muscles of the body when introduced 
systemically. Therefore, the uptake of PMOs to other muscles of the body during 
MBUS treatment of the heart was tested. Results showed that MBUS treatment of the 
heart did not negatively affect PMO uptake in other muscles. It has been speculated 
that PMOs are taken up by muscle fibres by passive diffusion most likely due to their 
small molecular weight and uncharged nature. Injections of a PMO and Optison 
combined showed increased uptake of PMOs compared to injections of PMOs alone. 
These results show that MBUS treatment of the heart has the potential not only to 
induce dystrophin expression in the heart, but also to allow the systemic treatment of 
all muscles. Furthermore, MBUS treatment of skeletal muscle was also successful in 
improving the number of dystrophin-positive fibres. Such treatment of skeletal 
muscle could be used for localised treatment of muscles (e.g. in an arm or hand), 
which could improve the independence of patients in more advanced stages of DMD. 
 
Optimisation of the MBUS settings showed that microbubble concentration is 
a key factor in improving gene uptake. The data show that injections with increased 
Optison concentration yielded better dystrophin expression in cardiomyocytes. This 
could be due to the large number of microbubbles present in the blood stream 
increasing the chance of more bubbles being in close proximity to the membrane. 
More microbubbles in close proximity of the membrane would increase the number 
of transient pores forming. However, the microbubble concentration has to be 
carefully optimised with regards to safety. Experiments using microbubble 
concentrations higher than 1-2×109 bubbles/mL showed some fatalities in mice due to 
an embolism, occurring either due to the high concentration of bubbles in the blood 
or to gas bubbles in the syringe that could not be seen due to the turbid nature of the 
bubble solution (see section 6.2.2.2). Although high numbers of microbubbles would 
improve the effectiveness of MBUS, any improvement gained may come at the 
expense of safety. Therefore, further investigations are required into the use of other 
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commercially available microbubbles in order to identify a microbubble that gives the 
best results at the lowest bubble concentration. 
 
A further parameter that is central to MBUS is the mechanical index (MI). 
The MI is an indication of the likelihood that inertial cavitation will occur. At higher 
MI, it is more probable that the microbubbles will collapse. The current consensus is 
that transient pore formation occurring during MBUS is primarily caused by this 
inertial cavitation and consequently increasing MI will cause more of the 
microbubbles to collapse leading to a more effective MBUS treatment. In order to 
investigate this hypothesis, a range of MIs were tested. Results showed however, that 
higher MIs did not result in higher numbers of dystrophin-positive cardiomyocytes. 
There are two hypotheses as to why the results do not show the expected trend. 
Firstly, by increasing the MI, the behaviour of the microbubbles is subject to change 
and therefore the mechanism of delivery may be altered. By increasing the MI 
(measured value) from 0.71 to 0.93, it is assumed that a larger population of 
microbubbles would undergo inertial cavitation earlier, with a shortened period of 
oscillation. It may be the case that an MI of 0.71 allowed the microbubbles to 
oscillate for a longer period before collapsing, while an increase in MI above 0.71 
induced cavitation earlier. The data shown here demonstrate that an MI setting of 
0.93 did not result in an increase in efficiency of gene delivery above that observed 
for an MI setting of 0.71. Furthermore, in order to achieve the same level of gene 
delivery an MI of 1.03 was required.  A reason for this may be due to a different 
mechanism of pore formation occurring at higher MI’s, one which depends on 
cavitation alone. This is in contrast to a mechanism operating at low MI’s which 
would depend on a combination of oscillation and cavitation. Put another way, the 
combination of oscillation and cavitation may be more efficient at pore formation and 
gene delivery than cavitation alone. This may explain why an MI setting of 0.71 is 
more efficient than 0.93, and why an increase in MI to 1.03 is required to achieve a 
comparable outcome to the lower setting. It would be interesting to discover if MI 
settings higher that 1.03 could achieve higher efficiencies due to increased cavitation, 
however the limitations of the Siemens Acuson Sequoia would mean a therapeutic 
ultrasound scanner would be required for such settings, making a direct comparison 
difficult. 
 142
 
The second hypothesis for the unexpected trend observed is that the 
transducers used are different in size (see Fig. 3.2). The 7V3c transducer is much 
smaller and therefore the target may not have received equal ultrasound exposure. 
Furthermore, due to the differences in the frequency settings, the imaging quality was 
poorer using the 7V3c transducer. This poorer image quality may have also 
contributed to poor targeting of the heart. If this hypothesis is the case, then this 
experiment was more a comparison of different transducer size, rather than the use of 
different ultrasound settings  
 
Although there still is further optimisation to do and certainly functional tests 
of the MBUS treated hearts would be desirable, the data presented here clearly 
demonstrate, MBUS can be successfully used to induce dystrophin-positive 
cardiomyocytes in the mdx heart whilst allowing PMO uptake in other muscles 
throughout the body. Moreover, no detectable damage was observed in the 
myocardium either 24 hours or 7 days after treatment, demonstrating that MBUS 
treatment can be safely applied repeatedly. The data also show that microbubble 
ultrasound is potentially a very valuable addition towards a complete systemic 
treatment of DMD using PMO-mediated exon skipping. 
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6 Optison compared to other microbubbles 
 
6.1 Introduction 
 
In an attempt to further improve the efficiency of MBUS, a number of types of 
microbubbles were investigated. It had already been established that different 
commercially available microbubbles showed different efficiencies when used for 
ultrasound mediated gene delivery132, 194. Therefore, in this chapter three types of 
commercially available microbubbles were compared for their use in MBUS. Their 
size, concentration and behaviour of the bubbles in an ultrasound field was analysed 
in order to identify the useful attributes of a given microbubble for MBUS 
applications. 
 
The three microbubbles studied were Optison, SonoVue and Sonazoid. Optison 
had already been used in the beginning of this study as the microbubble with the most 
potential to show efficient gene delivery, as suggested by Wang et al132. Optison has a 
human serum albumin (HSA) shell around an octafluoropropane gas bubble. 
According to the manufacturer, Optison has a median diameter of 3-5µm and is 
supplied in a concentration of 5-8×108bubbles/mL. As discussed in Chapter 1, 
Optison has been used for a variety of MBUS approaches and has successfully 
improved gene delivery to a range of target organs (Table 1.1 & 1.2). SonoVue, a 
stabilised sulphur hexafluoride microbubble surrounded by a phospholipid shell, has 
also been tested for use with MBUS and showed good efficiencies with therapeutic 
ultrasound (1-2MHz) in vitro195, 196. According to the manufacturer, SonoVue has a 
mean diameter of 2.5-6µm and an average concentration of 2-5×108bubbles/mL. 
Sonazoid however is a new microbubble that is currently only licensed in Japan. 
Sonazoid is a perfluorobutane gas microbubble stabilized by a lipid shell in a sucrose 
matrix, with a median diameter range of 2.3-2.9µm and an average concentration of 
0.8-1.5×109bubbles/mL197. Sonazoid is under investigation for detection and 
characterisation of hepatic tumours198, but has not been extensively studied for use in 
MBUS. In vitro results demonstrated by Howard et al. have shown that Sonazoid can 
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improve adenoviral delivery to cultured cells when insonicated with 4MHz, 565kPA 
US199. 
 
Two groups have so far compared different commercial microbubbles in order 
to find the best bubble for MBUS applications. Both groups demonstrated that 
Optison was the most efficient microbubble for gene delivery into skeletal muscle 
when combined with 1MHz, 20% duty cycle ultrasound for 20-30 seconds131, 132. 
SonoVue was found to be less efficient than Optison, as were the microbubbles 
Albunex and Levovist. Levovist was also found to increase tissue damage. However a 
major caveat of these studies is that both groups did not equalize microbubble 
concentrations when they compared the different bubbles types. Furthermore, Wang’s 
group also made an interesting observation when they compared gene delivery with 
Optison alone and Optison combined with US132. Their data showed that Optison 
alone was just as efficient as Optison with US. This however was not confirmed by Li 
et al131. In Chapter 4, it was shown that when high concentrations of plasmid were 
injected with Optison alone, a small but statistically insignificant increase was 
observed in the liver compared to plasmid alone (Fig.4.2). In combination with data 
from Wang et al., it can be concluded that Optison appears to have a small innate 
effect on gene delivery. In contrast, microbubbles such as SonoVue, which do not 
show such an innate effect, have a different chemical composition. Moreover, the 
unique chemical composition of Optison is so far the only explanation for its superior 
efficiency in gene delivery. 
 
There are however a variety of factors that could influence the efficiency of a 
microbubble for gene delivery. Apart from their shell and gas chemistries (which is 
linked to pH, charge and interaction characteristics), the size and concentration of a 
microbubble population as well as their stability could play a role for gene delivery. 
Therefore, in this chapter the efficiencies of the three chosen microbubbles for gene 
delivery were investigated, and their size, concentration and stability was analysed in 
order to further clarify which are the influential factors. 
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6.2 Results 
 
6.2.1 Analysis of microbubbles 
 
Commercially available microbubbles at the moment differ from each other in 
concentration, size distribution and chemical properties. All of these parameters will 
influence the bubbles behaviour in an ultrasound field and therefore their use in 
MBUS. To be able to accurately quantify these parameters would allow a better 
understanding of their role in MBUS for gene delivery, and would also help to 
optimize the technique. Although the manufacturers do give some indication of the 
bubble concentration and size, it is too vague to allow valid conclusions to be drawn. 
Therefore, microbubbles used for MBUS mediated gene delivery were accurately 
counted and sized, and their stability out of and inside an ultrasound field was tested. 
 
6.2.1.1 Microbubble concentration 
 
Before microbubbles could be accurately counted, the pros and cons of the 
techniques available had to be considered. Within our lab, there are 2 techniques 
available: electrical zone sensing using a Coulter Multisizer II (Coulter Electronics 
Limited, Beds, UK) and an optical and image-based computational algorithm that 
was developed by Dr Eckersley and myself.  
 
The Coulter Multizer is able to count and size a large number of microbubbles 
and therefore can establish an accurate size distribution. However, one limitation of 
this technique is the aperture. A precision aperture with a diameter of 30µm is 
employed for our Coulter Multisizer II allowing our system to analyze particle 
concentration and size distribution from 0.6 to 18µm in diameter. This means that 
microbubbles smaller than 0.6µm are not taken into consideration. Moreover, the 
Coulter Multisizer cannot distinguish between one large bubble and two small ones 
stuck together, which could lead to wrong trends in the size distribution and 
concentration.  
 
Deleted: e
 146
The optical method (OM) is a conventional counting method, where pictures 
of bubbles are taken on a haemocytometer grid and then run through a MATLAB 
based computer program for counting and sizing. One advantage is that the accuracy 
of the process can be overseen manually. Before the images of the bubbles were 
captured, the distribution of the bubbles was checked. If bubbles started to aggregate, 
the dilution was adjusted to ensure evenly dispersed bubbles for most accurate 
analysis. During the computer analysis, the program allowed the user to visualize and 
quantify how accurately the bubbles are counted and sized by drawing a green ring 
around each counted and sized bubble and a red cross through each rejected bubble 
(Fig.6.1A). Rejection is most likely due to two or more bubbles sticking together. The 
MATLAB software then gives a total account of the number of counted and rejected 
microbubbles. A limitation to this method however is the optical resolution, which 
may limit the range of bubbles that can be detected. The resolution is related to 
numerical aperture, magnification of the lens and the pixel density of the image taken. 
In this experimental set up a ×20 objective with a numerical aperture of 0.5 was used. 
Pictures were taken by a digital CCD camera (Nikon) with a pixel density of 
4116×3072. Using this set up, the limiting factor was the pixel density of the captured 
image. The smallest bubble that could be detected was the size of one pixel (0.08µm). 
For accuracy, the minimum size limit was set to 2× the smallest pixel, which means 
the smallest microbubble size that was accurately detected was 0.16µm. 
 
  Because the optical method allows the user to manually and quantitatively 
oversee the accuracy of the count, and the size range that can be accurately detected 
is wider than the Coulter Multisizer, OM was chosen for all microbubble counts. 
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Figure 6.1: MATLAB readout for counting and sizing calibration beads of (A) 1µm 
and (B) 5µm. Green rings show counted and sized beads, red crossed mark rejected 
beads. Readouts provided by Dr Eckersley and Dr Sennoga. 
 
A 
B 
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In order to ensure that the OM computer program accurately measures the size 
of microbubbles, 1µm and 5µm calibration beads were used to test and calibrate the 
system (calibration done by Dr Eckersley and Dr Sennoga). The program was able to 
accurately detect both size beads with minimal variation (Fig.6.1).  
 
 In order to rule out the possibility that the ×200 magnification failed to 
detect very small bubbles in the solution, which could lead to a false concentration 
measurement, images of a SonoVue dilution were captured on a ×40 and ×100 
objective in an attempt to find smaller microbubbles not detected by the ×20 
objective. SonoVue was chosen as the manufacturer’s information indicated that it is 
the smallest of the three microbubbles analysed. Captured images showed that even 
on a ×100 objective, few if any bubbles were seen that were not visible on the ×20 
objective (Fig. 6.2).  
 
The concentration of the three microbubbles Optison, SonoVue and Sonazoid 
was then measured by the calibrated OM system (section 2.15). The concentration of 
each microbubble, when prepared according to manufacturer’s instructions, is 
displayed in table 6.1. If microbubbles were prepared according to manufacturer’s 
instruction, they will be referred to as neat. Variations seen in the reading could be 
due to variations between vials of microbubbles, but also human error (pipetting 
error) has to be taken into consideration.  
 
 
Table 6.1: Summary of concentrations and sizes of Optison, SonoVue and Sonazoid 
as determined experimentally by Optical Microscopy compared to manufacturers 
information. 
 Concentration 
(bubbles/mL) 
Concentration 
(bubbles/mL) 
according to manufacturer 
Median Size 
(µm) 
Size (µm) 
 
according to 
manufacturer 
Optison 8.6×108 +/- 8% 5-8×108 2.15 +/- 0.19 3-5 
SonoVue 4.16×108 +/- 12% 2-5×108 1.17 +/- 0.04 2.5-6 
Sonazoid 2.44×109 +/- 3% 0.8-1.5×109 1.44 +/- 0.01 2.3—2.9 
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Figure 6.2: Microscope images of SonoVue (diluted 1:100 in Saline) taken with a 
(A) ×40 objective and a (B) ×100 objective. 
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6.2.1.2 Size distribution of microbubbles 
 
The size distributions of Optison, SonoVue and Sonazoid were established 
using the optical method described in the previous section. The microbubble sizes 
were grouped into bins of 0.25µm. Standard error on graphs show variations between 
vials (n=3).  
 
Comparison of the size distribution showed that all three microbubbles have 
different size distributions (Fig. 6.3). Optison has the widest size range. Most Optison 
microbubbles are between 1.5 and 3µm in size. Fig. 6.3A shows SonoVue and 
Sonazoid have a narrower range, with the most common SonoVue microbubble size 
at about 1µm, whereas for Sonazoid the most common size is about 1.75µm. 
Although all three microbubbles show different size distributions, the microbubble 
ranges resembling each other the most are SonoVue and Sonazoid. 
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Figure 6.3: Size distribution (diameter) of Optison, SonoVue and Sonazoid displayed 
as (A) % of microbubbles per mL and (B) % volume. Bin size of each data point is 
0.25µm. 
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6.2.1.3 Stability of microbubbles  
 
In order to make an estimate about the stability of the microbubbles outside an 
ultrasound field, microbubble concentration was followed over 7 days during which 
the solutions were kept at 4°C. At day 1 and day 7, microbubble concentration was 
measured using OM (section 2.15). The decrease in concentration over time allowed 
us to identify which microbubble was the most stable.  
 
Over 7 days, the concentration of Optison decreased by 21.5% (Fig. 6.4). 
Sonazoid showed a similar decline in concentration, decreasing by 17% over 7 days. 
The concentration of SonoVue however decreased by 79% over 7 days. The loss of 
microbubbles of SonoVue was significantly different compared to Optison and 
Sonazoid (P<0.001). It has to be noted that the chemical structure of SonoVue is most 
similar to Sonazoid. However, a detailed comparison of the chemical composition of 
SonoVue and Sonazoid was not possible due to the lack of details provided by the 
manufacturer. 
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Figure 6.4: Percentage of decrease in concentration over 7 days of Optison, SonoVue 
and Sonazoid (*P<0.001,**P<0.001, n=3). 
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6.2.1.4 Stability of microbubbles in an ultrasound field (in vitro) 
 
In order to investigate how the different microbubbles behave in an ultrasound 
field, microbubbles in a beaker were subjected to an ultrasound field (section 2.16). 
Microbubbles were diluted in 37°C PBS. The first 5mm of the ultrasound transducer 
previously used for all in vivo experiments (Siemens Acuson Sequoia, 15L8) was 
immersed in the solution, and was set to transmit either a low destruction ultrasound 
beam at a C14MHz MI 0.59 setting, or the high intensity US beam used so far for in 
vivo experiments, H14MHz, MI 1.8, with a focus half way down the beaker (3cm) 
(Fig. 6.5). A stirrer ensured the even distribution of microbubbles in the beaker. Once 
the microbubbles were evenly distributed and the probe was in place, the first 
ultrasound image was captured using the C14MHz setting (Fig 6.6A). Although this 
setting should not induce much damage, it was only turned on for the second that it 
took to capture the ultrasound image. Then, 20 seconds of H14MHz ultrasound was 
transmitted (Fig. 6.6B). Immediately after the 20 second ultrasound, another image 
was taken at C14MHz (Fig 6.6C). In order to ensure that microbubbles didn’t get 
destroyed by C14MHz ultrasound or the stirrer, a negative control group was tested 
without H14MHz ultrasound for 20 seconds. The concentration of the three 
microbubbles tested were equalized to be ~ 8×108bubbles/mL and diluted in PBS to a 
final concentration of 2.5×105bubbles/mL. 
 
In order to quantify the destruction that occurred during exposure to 
ultrasound, the level of video intensity of the B-mode image was measured in a 
section of the image (blue box, Fig. 6.6). Black was assigned the value of 0, the value 
for white was 255. Values of video intensity before and after exposure to 20 second 
H14MHz US were determined for each microbubble (Appendix Table 9.1) using the 
ultrasound images captured (example images for SonoVue, Fig. 6.3, examples for 
Optison and Sonazoid, Appendix, Fig. 9.3 & 9.4). In this experiment, logarithmic 
conversion was not taken into consideration, but as all images were treated exactly 
the same so that the change in the video intensity could be used as an indicator of 
how much microbubble destruction took place.  
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Figure 6.5: Model of set up used for microbubble destruction studies. A Siemens 
15L8 transducer was placed in a beaker filled with a microbubble-PBS solution. A 
stirrer ensured even distribution of the bubbles 
A 
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Figure 6.6: B-mode ultrasound images of SonoVue taken (A) before 20 seconds of 
H14MHz US exposure (B) during US and (C) immediately after US exposure. 
A 
B 
C 
 157
 The destruction experiment showed that the concentration of SonoVue 
decreased the most when subjected to the 20 seconds ultrasound exposure (Fig. 6.7). 
Both Optison and Sonazoid were significantly more stable (P<0.035, P<0.04, 
respectively). No difference was seen in destruction of Optison and Sonazoid. The 
negative control group showed that without the exposure to the H14MHz US, all 
three microbubble types were stable with only minimal destruction seen during a 20 
second interval. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.7: Changes in video intensity of the B-mode ultrasound images as an 
indicator for changes in microbubble concentration due to insonication of the 
microbubble solutions with H14MHz, MI 1.9 US for 20 seconds. Negative control 
did not receive any ultrasound for 20 seconds. US images for both groups were taken 
at the same time points using C14MHz, MI 0.59 US (*P<0.035, **P<0.04, n=3) 
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6.2.2 Gene delivery to heart with US and Optison, SonoVue and Sonazoid 
 
In order to compare the efficiencies of the different microbubbles (MBs) for 
MBUS mediated gene therapy, the same delivery protocol was used for all 
experiments. 200µg JAC1 was injected with 150µL MBs in a total volume of 200µL 
into the tail vein of anaesthetised C57BL10 mice and US (H14MHz, MI 1.8) was 
applied to the heart with the 15L8 transducer of the Siemens Acuson Sequoia for 2 
minutes. The only variable factor was microbubble type and concentration. 
 
 
6.2.2.1 Delivery of JAC1 to heart using MBUS - equalised concentrations 
 
In order to test the use of SonoVue and Sonazoid for use in MBUS, both 
microbubbles were prepared to be of equal concentration as Optison. Therefore, 
SonoVue was prepared in half the usual volume of saline and Sonazoid was diluted 
1:3 in saline. 150µL of 8×108bubbles/mL SonoVue and Sonazoid were injected with 
plasmid and US was applied to the heart as described previously (section 6.2.2). The 
results were compared to Optison used in the same experimental set up. 
 
Results show that SonoVue was the least efficient microbubble for MBUS 
gene delivery (Fig. 6.8). Hearts treated with SonoVue MBUS showed significantly 
less luciferase activity compared to heart treated with Sonazoid MBUS (P<0.05). 
Sonazoid MBUS resulted in luciferase activity of the same level than Optison MBUS, 
with no significant difference. 
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Figure 6.8: Average photon flux resulting from luciferase activity in mouse heart 7 
days after injection of 200µg JAC1 combined with SonoVue, Optison and Sonazoid 
and US treatment of the heart (2x SonoVue: 2x concentrated SonoVue, Optison: neat 
Optison, 1:3 Sonazoid: 1:3 diluted Sonazoid, *P<0.05, n=5). 
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6.2.2.2 Optimum concentration for each microbubble type 
 
In Chapter 5 it was established, that when double the Optison microbubbles 
were used for MBUS, a significant increase could be seen (section 5.2.5). In order to 
investigate if a higher microbubble concentration could also improve the MBUS gene 
delivery with SonoVue and Sonazoid microbubbles, both of them were prepared in 
the highest concentration thought possible. Therefore, SonoVue was prepared in a 
quarter of the volume of saline (1.25mL) provided by the manufacturer. Sonazoid 
was reconstituted in 1mL saline, half the volume intended by the manufacturer. Both 
concentrations were measured by OM, revealing that 4x SonoVue resulted in 
concentration of 1×109 bubbles/mL, 2x Sonazoid in a concentration of 4×109 
bubbles/mL. 150µL of the concentrated bubble solutions were used to give MBUS 
treatment to the heart, as described before (section 6.2.2). 
 
Using the concentrated solutions of SonoVue and Sonazoid showed that again 
SonoVue was the less efficient microbubble (Fig. 6.9). Doubling the concentration of 
SonoVue did not achieve a significant increase in luciferase activity (P<0.08). 
Concentrating Sonazoid on the other hand did achieve a significant increase (P<0.03) 
compared to the 1:3 dilution. Moreover, it is important to note that concentrated 
SonoVue (1×109bubbles/mL) achieved the same level of gene delivery as the diluted 
Sonazoid (8×108bubbles/mL) (P<0.5). This showed that Sonazoid required fewer 
microbubbles compared to SonoVue to achieve efficient gene delivery.  
 
The highest level of luciferase expression overall was achieved using 
concentrated Sonazoid (Fig. 6.9). However, it has to be considered that Sonazoid was 
very highly concentrated, a concentration that was only possible because neat 
Sonazoid is already very highly concentrated, 6x higher than neat SonoVue and 3x 
higher than Optison. This allowed Sonazoid to be concentrated even further, which 
allowed for the significant improvement. As already discussed in Chapter 5, injecting 
a highly concentrated microbubble solution can cause emboli. In this set of 
experiments, mice fatalities did occur when the highly concentrated solutions were 
injected either due to the high numbers of microbubbles injected or due to the 
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injection of an air bubble in the syringe that could not be seen due to the turbid nature 
of the concentrated microbubble solution. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.9: Average photon flux resulting from luciferase activity in mouse heart 7 
days after injection of 200µg JAC1 combined with SonoVue and Sonazoid at 
different concentrations and US treatment of the heart (2x SV: 8×108bubbles/mL 
SonoVue, 4x SV: 1×109bubbles/mL, 1:3 SZ: 8×108bubbles/mL Sonazoid, 2x SZ: 
4×109bubble/mL *P<0.08, **P<0.03, #P<0.5, n=4). 
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6.2.3 Improving gene delivery using concentrated Sonazoid and US 
 
Due to the findings that concentrated Sonazoid resulted in the highest levels 
of reporter gene delivery to the heart (section 6.2.2.2), it further experiments were 
conducted to see if concentrated Sonazoid could improve reporter gene delivery to 
the liver, and also PMO delivery to the mdx heart. 
 
6.2.3.1 Reporter gene delivery to the liver using concentrated Sonazoid and US 
 
In order to investigate if concentrated Sonazoid could improve reporter gene 
delivery with MBUS to the liver, 150µL of concentrated (2x) Sonazoid 
(4×109bubbles/mL) combined with 250µg pEGFPluc were injected into the tail vein 
of a mouse and 2 minute US exposure was given to the liver (section 2.7) The results 
were compared to MBUS to liver using neat Optison (8×108bubbles/mL). 
 
The results showed that there was a trend in favour of the MBUS treatment 
with concentrated Sonazoid, however the increase was not statistically significant 
(Fig. 6.10, P<0.3). The large variation seen for Sonazoid was most likely due to 
Sonazoid’s susceptibility to problems with the IV injections. It was observed that 
when a small part of the injection was given into the tail tissue, rather than the tail 
vein, the pressure that build up in the syringe due to the resistance of the tail tissue 
caused some of the Sonazoid bubbles to break down, which was observed by the 
solution becoming clearer (normal concentrated Sonazoid solution is very turbid). 
This susceptibility to the pressure caused by a misplaced IV injection was only 
observed for Sonazoid, but not for SonoVue or Optison.  
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Figure 6.10: Average photon flux resulting from luciferase activity in mouse liver 7 
days after injection of 250µg pEGFPluc combined with neat Optison or concentrated 
Sonazoid. The increase seen for concentrated Sonazoid is not statistically significant 
(P<0.3, n=3). 
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6.2.3.2 PMO delivery to the mdx heart using concentrated Sonazoid and US 
 
In order to investigate if concentrated Sonazoid could improve delivery of 
PMOs to the myocardium of mdx mice, standard injections with 16mg/kg PMOs 
were repeated (section 2.10), this time using 150µL diluted (1:3), neat and 
concentrated (2x) Sonazoid. The results were compared to MBUS treatments done 
with single and double volume Optison (section 5.2.5). An overview of the 
microbubble concentrations and the total number of microbubbles injected in a 
150µL volume can be seen in table 6.2. It has to be noted that the highest number of 
Optison bubbles injected (in a 300µL volume) was 2.4×108, whereas the highest 
number of Sonazoid microbubbles injected (when 2x concentrated) was 6×108. In 
order to compare Sonazoid to Optison with equal microbubble numbers, Sonazoid 
was diluted 1:3 to achieve the same concentration as Optison. In order to investigate 
if Sonazoid MBUS is safe, histological analysis was carried out on heart treated with 
MBUS using diluted and neat Sonazoid. 
 
 
 
 
 
Table 6.2: Overview of microbubble concentrations and total number of 
microbubbles in a 150µL volume. 
 
Microbubble Concentration 
(bubbles/mL) 
# of bubbles in 
150µL 
 Optison 8×108 1.2×108 
Optison double volume 8×108 2.4×108* 
1:3 Sonazoid 8×108 1.2×108 
Sonazoid 2.4×109 3.6×108 
2x Sonazoid 4×109 6×108 
*in 300µL 
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Figure 6.11: Restoration of dystrophin positive cardiomyocytes in mdx heart 7 days 
after injection with 16mg/kg PMOs in combination with 150µL (and once 300µL) 
MBs followed by a 2 minutes US exposure to the heart (SZ: Sonazoid; for numbers 
of microbubbles injected see table 6.2, *P<0.02, n=5). 
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Results showed that for the delivery of PMOs into mdx heart, Sonazoid and 
Optison have a similar effect when the numbers of microbubbles were equalized, with 
no difference in numbers of dystrophin positive cardiomyocytes detected 7 days after 
MBUS treatment (Fig. 6.11), a trend already seen in section 6.2.2.1. When Sonazoid 
was used in a more concentrated from, a significant increase in dystrophin positive 
cardiomyocytes was seen when numbers of Sonazoid bubbles injected from 1.2×108 
to 3.6×108 (*P<0.02). However, no further increase was seen when numbers of 
bubbles were increased to 6×108. Furthermore, injections with 2.4×108 Optison 
bubbles were just as efficient as injections with 6×108 Sonazoid bubbles. 
 
Histological analysis of hearts treated with MBUS with diluted and neat 
Sonazoid showed no signs of tissue damage (Fig. 6.12). Therefore, Sonazoid would 
also be a candidate microbubble for repeated injections for the treatment of DMD. 
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Figure 6.12: H&E stains of C57BL10 myocardium taken 24 hours after MBUS 
treatment of the myocardium with (A) Sonazoid and (B) 1:3 diluted Sonazoid. Scale 
bar indicated 200µm. 
A 
B 
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6.2.3.3 Repeated PMO injections to the mdx heart with diluted Sonazoid and US 
 
Sonazoid has been shown to be a microbubble useful for MBUS gene delivery, 
as it showed similar efficiencies as Optison (section 6.2.3.2). Sonazoid also has the 
advantage that it has a phospholipid shell, rather than a human serum albumin shell. 
Especially for pre-clinical experiments in mice, this is an advantage as repeated 
injections are possible without provoking an immune response. In order to investigate 
if Sonazoid is able to be safely administered repeatedly without provoking an 
immune response, repeated MBUS treatments with diluted Sonazoid 
(8×108bubbles/mL) were given. Injections with 16mg/kg PMOs and 2 minutes US to 
the heart were given in weekly intervals up to 3 times.  
 
The results showed that repeated injections were successful, with a significant 
increase in dystrophin positive cardiomyocytes with every additional treatment given 
(Fig. 6.13 & 6.14, *P<0.003, **P<0.1). Moreover, mice treated with more than one 
injection were healthy with no signs of adverse effects to the treatment. This allowed 
the conclusion that problems observed with Optison were only due to the chemical 
composition of the bubbles, and were not due to the repeated MBUS treatment. 
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Figure 6.13: Immunofluorescence images of myocardium from mdx mice treated 
with single (A), double (B) and triple (C) intravenous injection of PMOs plus MBUS 
using 1:3 diluted Sonazoid. Sections were stained for dystrophin with rabbit 
polyclonal antibody P7 and counterstained with DAPI to show nuclei. Scale bar 
indicates 200µm. 
A 
B 
C 
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Figure 6.14: Expression of dystrophin positive cardiomyocytes in mdx myocardium 
after 1, 2 and 3 injections of PMOs with MBUS using 1:3 diluted Sonazoid. 
Significant increase in dystrophin-positive cardiomyocytes per section of mdx 
myocardium was seen for each repeated injection given (*P<0.003, **P<0.01, n=3). 
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6.3 Discussion 
 
In this chapter, it has been shown that not all commercially available 
microbubbles exhibit the same efficiencies for gene delivery with MBUS. The main 
findings of the in vivo experiments, which compared the efficiencies of the different 
microbubbles, showed that gene delivery using Sonazoid microbubbles was very 
similar to Optison microbubbles. SonoVue microbubbles however, were less efficient 
for MBUS gene delivery. This finding was surprising, because the most common 
explanation for the apparent better efficiency of Optison over other microbubbles was 
its HSA shell composition. Microbubbles with phospholipid shells, such as SonoVue 
were so far less efficient when used for MBUS gene delivery. Sonazoid however, also 
has a phospholipid shell, and therefore one would expect Sonazoid to behave in a 
similar manner to SonoVue rather than Optison. Therefore, this observation suggests 
that the chemical composition in itself does not play a critical role in MBUS gene 
delivery, as a phospholipid microbubble can be just as efficient as a HSA 
microbubble at equal concentrations. However, this by no means implies that the 
shell chemistry does not influence MBUS efficiency, on the contrary, the shell plays 
an important part in the stability and size distribution of the microbubble population. 
Analysis of the size distributions of the three microbubbles showed that Optison 
differs significantly from SonoVue and Sonazoid. Optison has a very wide range of 
sizes. The sizes of SonoVue and Sonazoid are over a smaller and narrower range. 
Therefore, it is likely the case that size distribution has little influence on MBUS gene 
therapy, as Sonazoid and SonoVue have a similar size distribution but behave very 
differently in vivo. A further parameter investigated here that does appear to correlate 
with the observations made in vivo is the stability of the microbubbles. The stability 
was measured both with and without the influence of an ultrasound field, and both 
results showed that SonoVue is a fragile microbubble, which degrades faster under 
both conditions. Optison and Sonazoid were very similar in terms of stability in the 
presence and absence of an ultrasound field. This data demonstrates that stability of 
the bubbles is a major influencing factor on the efficiency of MBUS mediated gene 
delivery. Microbubble stability is most likely determined by both the shell chemistry 
and the type of gas inside the bubble. However, in this study, only few microbubble 
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characteristics were investigated. More detailed analysis of microbubbles will be 
necessary to understand the important microbubble characteristics which influence 
MBUS gene delivery. Analysis should therefore concentrate on shell characteristics 
such as flexibility, charge, pH, and other microbubble components such as gas.  
 
This study has shown that SonoVue was not as efficient for gene delivery as 
Optison or Sonazoid when bubble concentrations were equal. However, it was shown 
that when the concentration of SonoVue was increased, gene delivery efficiency 
comparable to the other microbubbles tested was achieved. As discussed in chapter 5, 
the observation that efficiency increases with microbubble concentration is most 
likely due to an increased possibility of the microbubbles being present in close 
proximity to the membrane. This might lead to an increase in the number of transient 
pores formed, in turn resulting in an increase in gene delivery. This suggests that 
most microbubbles can be used for MBUS, however the concentration required to 
achieve gene delivery might compromise safety, as high concentrations carry the risk 
of causing emboli.  
 
Thus far, the most efficient results were achieved using MBUS with Optison 
and Sonazoid. Compared to SonoVue, Sonazoid and Optison showed best results 
with the smallest numbers of microbubbles injected, having similar efficiencies at 
lower concentrations. It was also shown that the gene delivery efficiency of both 
microbubbles increased proportionally with concentration, however this was only 
observed up to a concentration of ~2.5×109 bubbles/mL.  Increasing concentration of 
Sonazoid injected from 2.4×109 to 4×109bubbles/mL failed to result in an increase in 
the numbers of dystrophin positive cardiomyocytes restored. This observation 
suggests that DNA (here PMOs) concentration was limiting at this higher 
microbubble concentration. While PMOs were shown not to be the limiting factor for 
injections using up to 8×108 bubbles/mL, it may be the case that by increasing bubble 
concentration further this would eventually lead to the PMO concentration limiting 
the efficiency of the treatment. An alternative hypothesis for the observation that a 
higher concentration of microbubbles does not improve gene delivery further is that 
at higher microbubble concentration, the ultrasound beam is attenuated strongly by 
the dense microbubble population. This could result in a weaker ultrasound wave or 
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even a shadow in deeper tissue which could impede any beneficial effect the higher 
microbubble concentration has on gene delivery. These hypotheses may explain the 
observation that 2.4×108 bubbles of Optison had the same effect as 6×108 bubbles of 
Sonazoid, although at lower concentrations they have been shown to have similar 
efficiencies. However, this result may also suggest that an unknown microbubble 
parameter other than stability is also influential for MBUS gene delivery, which may 
explain the increased performance of the Optison bubble relative to the Sonazoid 
bubble. It is perhaps more likely that there is an optimal bubble/DNA ratio, therefore, 
if microbubble concentration is increased, it would be necessary to adjust the DNA 
concentration in order to continue to see an improvement. However, microbubble 
concentration cannot be increased without consequence, as the safety of the treatment 
must be paramount. Injections with high numbers of microbubbles would result in an 
increased risk of embolism, and as such preference should be given to the lowest 
microbubble concentration that can achieve a satisfactory level of gene delivery. 
 
If an optimal ratio could be identified, the need to inject excess amounts of 
DNA or microbubbles would be eliminated, allowing this treatment to be more cost 
effective. Further testing with concentrated Sonazoid and higher concentrations of 
PMOs is needed to allow further conclusions to be drawn regarding this aspect of 
MBUS.  
 
Finally, Sonazoid was shown here to be as efficient as Optison when used at 
lower concentrations, and so Sonazoid may also be a useful candidate for repeated 
injections with PMOs for the treatment of DMD. The advantage of Sonazoid is that it 
has a phospholipid shell, which makes it a more attractive microbubble for human 
application. Due to Optison’s HSA shell, there is a risk of transmitting viral or prion 
diseases. No such risk exists for Sonazoid. Therefore, the use of Sonazoid could 
ensure risk factors are kept to a minimum. Moreover, the fact that Sonazoid does not 
contain any human derived components allows repeated injections in a pre-clinical 
setting to be carried out without provoking an immune response. Results of repeated 
MBUS treatments of mdx mice showed that Sonazoid MBUS can be administered 
regularly without any signs of adverse effects, while achieving accumulation of 
dystrophin positive cardiomyocytes with each treatment. It has to be noted however, 
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that the repeated treatments were given using diluted Sonazoid, therefore results 
could be improved upon by using higher concentrations of Sonazoid, and 
optimization of the bubble/DNA ratios could potentially improve efficiencies even 
further. 
 
7 Discussion and future work 
 
This project set out to investigate the potential of microbubbles in combination 
with diagnostic ultrasound (MBUS) to act as a safe and site-specific physical 
enhancer of gene delivery. Initially, a luciferase reporter gene was used to investigate 
the feasibility of this technique. An injection of the reporter gene was given 
systemically while the ultrasound probe was used to direct gene delivery to the organ 
of interest. Results showed successful reporter gene delivery to both organs targeted 
(liver and heart, chapter 4) when MBUS was used. Importantly, enhanced gene 
delivery was only seen when US and MBs were used in combination, as no 
significant improvement in gene delivery was observed when MBs or US were used 
separately. The intensity of diagnostic US alone is not enough to cause a 
sonoporation effect. MBs however are able to potentiate the effect of the US which in 
turn leads to improved gene delivery. Following the success of the feasibility study, a 
therapeutic approach was investigated. Data presented in chapter 5 demonstrated that 
MBUS successfully improved the delivery of Phosphorodiamidate Morpholino 
Oligomers (PMOs) into the heart of dystrophic mice (mdx) resulting in the expression 
of dystrophin, a muscle protein absent in the mdx mouse due to a genetic mutation. 
Moreover, no safety concerns came to light during this study. There was no tissue 
damage detected in MBUS treated organs, and the microbubbles used have been 
cleared for human application, and therefore no adverse effects are expected from the 
chemical make-up of the microbubbles. Overall, MBUS using commercially available 
microbubbles and diagnostic ultrasound shows great potential as a safe physical 
enhancer for non-viral gene therapy.  
 
In order to improve MBUS gene delivery, ultrasound and microbubble 
parameters were screened to find optimal settings. The parameters under investigation 
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were the dose of PMOs, microbubble concentration, duration of US exposure and US 
settings. The results established that the major influencing factor for MBUS is the 
concentration of the bubbles. Increasing the bubble number injected significantly 
increased the numbers of dystrophin positive cardiomyocytes, suggesting an increase 
in the levels of PMO delivered to the target. This was most likely due to the larger 
number of microbubbles present in the blood stream, increasing the chance of more 
bubbles being in close proximity to the cell membrane. However, the microbubble 
concentration has to be carefully monitored with respect to safety. It was observed 
that experiments using microbubble concentrations greater than 1-2×109 bubbles/mL 
resulted in some fatalities in mice due to embolisms, occurring either as a result of the 
high concentration of bubbles in the blood or air bubbles present in the syringe that 
could not be observed due to the turbid nature of the bubble solution. Although large 
numbers of microbubbles would improve the effectiveness of MBUS, any 
improvement gained may come at the expense of safety. Therefore, it is important to 
find a microbubble that is efficient even at lower concentrations. For this purpose, 
two further commercially available microbubbles, SonoVue and Sonazoid, were 
compared to Optison in an attempt to find an optimal bubble for MBUS. Comparing 
their efficiency in MBUS gene delivery showed that SonoVue is the least efficient 
microbubble for gene delivery, whereas Sonazoid and Optison showed very similar 
results. Analyses of the three microbubbles lead to the conclusion that one of the 
major factors influencing efficiency of MBUS is the stability of the microbubble, 
whereas size and the chemical composition of the shell did not have a significant 
effect. Although this study did not focus on the mechanism behind MBUS directly, 
this finding allows some conclusions to be reached regarding the mechanisms 
involved.  
 
This study has been the first to demonstrate: 
 
• The general utility of diagnostic ultrasound in combination with microbubbles 
as a physical enhancer to target a variety of  tissues 
• The comparison of characteristics of commercially available microbubbles 
and their use in MBUS 
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• The delivery of PMOs into the mdx myocardium without the use of viral 
vectors 
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Possible mechanisms of MBUS 
 
The most common hypothesis so far for microbubble enhanced sonoporation 
is that inertial cavitation of the microbubbles is most influential. Inertial cavitation 
results in shear stresses, microjets and microstreams that cause pores to form in cell 
membranes that are in close proximity. Another model suggests that oscillation of 
microbubbles alone, or stable cavitation, can result in a sonoporation effect. In this 
study (chapter 6) it was found that microbubbles that are more stable in an ultrasound 
field exhibit better efficiencies in MBUS gene delivery compared to more fragile 
microbubbles. It is likely that stable microbubbles will oscillate for a longer period in 
an ultrasound field before undergoing collapse compared with fragile bubbles, which 
would likely undergo collapse sooner. Therefore, it may be the case that oscillation 
plays an important role in MBUS gene delivery, as microbubbles that are more likely 
to oscillate for longer periods of time appear to be more efficient than microbubbles 
which collapse sooner. 
 
  Alternatively, this observation that a more stable microbubble is more 
efficient in MBUS gene delivery could also be used to validate the hypothesis that 
inertial cavitation is the primary event causing MBUS pore formation. Depending on 
the rigidity of the microbubbles, the energy required to undergo collapse will vary. A 
more fragile microbubble could require less energy to be pushed into an inertial 
cavitation event. Therefore, it will release less energy when collapsing, with 
consequently weaker microjets and microstreams. A more stable microbubble 
requires a higher energy input for inertial cavitation, therefore releasing more energy 
when undergoing collapse with stronger shear stresses. If inertial cavitation is the 
primary cause of MBUS sonoporation, it is possible that microbubbles able to absorb 
and release higher energy levels are more effective than those requiring less energy 
input for inertial cavitation, which could explain the observations made in chapter 6. 
 
In order to investigate the influence of stable and inertial cavitation further, 
Carbon Black200 (a dye usually used for vascular permeability assays) could be used 
to observe changes in permeability of blood vessles when under the influence of 
oscillating bubbles or bubbles undergoing inertial collapse, and the efficiency of both 
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could be compared. In order to control the behaviour of microbubbles in an 
ultrasound field, i.e. control stable oscillation or control time of cavitation, physical 
characterisation studies of the microbubbles will have to determine which US settings 
have to be applied to achieve the desired microbubble behaviour. Ideally, a system is 
required that is able to investigate individual bubble properties. It will be important to 
gain insight into conditions for both stable and inertial cavitation of an individual 
bubble, as this is difficult to infer from bulk measurements. Of particular interest will 
be measurements of the destruction threshold for individual bubbles and their 
stability in order to attempt to control their behaviour in vivo and in vitro. However, if 
microbubbles are analysed individually it has to be considered that a microbubble 
may behave differently when near a barrier such as a membrane. Therefore, in vitro 
studies with microbubbles near a cell layer should be performed to validate the 
accuracy of the information gained from the physical characterization of the bubbles. 
This would allow the investigation of two issues: i) The effect of the cell membrane 
on the acoustic properties and destruction thresholds of the bubbles and ii) The effect 
of the acoustic response of the bubbles on the cells themselves, using, for example, 
propidium iodide as a membrane integrity probe99, or by adding procion orange to the 
medium and imaging with fluorescent microscopy201.  
 
 
Location of MBUS influence 
 
Apart from the mechanism of MBUS, an area that has not received much 
focus in the literature is the issue of where MBUS act in vivo. In vitro data has shown 
that pores are formed in membranes of cells (chapter 1). However, when 
microbubbles are injected into the blood stream it is unlikely that they come in close 
contact with the cells of interest as the microbubbles are unlikely to cross the 
endothelial layer. Furthermore, it is known that for MBUS to be effective, 
microbubbles must be in close proximity to the cell membrane for a sonoporation 
effect to occur. Therefore, it is unlikely that MBUS induces pore formation in 
membranes of cells such as hepatocytes or cardiomyocytes that are located beyond 
the endothelial layer and therefore out of reach for a direct influence. The question 
therefore arises; does MBUS primarily aid plasmids to cross the endothelial layer 
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rather than the membrane of target cells? It is possible that MBUS disrupts 
endothelial cell junctions and therefore allows DNA to infiltrate the intercellular 
space of the target tissue. This could result in improved passive DNA uptake by the 
target cells. This is an important aspect of in vivo MBUS that will require further 
investigation. 
 
In order to investigate in more detail if microbubbles do not escape the 
vasculature, but instead act to improve the transport of plasmids across the 
endothelial layer, a series of in vivo experiments could assess the effects of MBUS on 
the microvasculature. An accessible and suitably thin muscle such as the cremaster 
muscle could be examined to compare the effect of systemic application of MBUS or 
VEGF202, as the latter is known to increase permeability of the blood vessels, which 
could be demonstrated using the dye Carbon Black. A comparison between the effect 
of MBUS and VEGF on the microvasculature would provide important information 
about the mechanism of MBUS in vivo, as it could reveal the location MBUS’s 
influence during gene delivery. Further experiments should aim to detect 
fluorescently labeled plasmid or dye (FITC-dextran) in or around the endothelium117 
in order to achieve a better understanding about the path of DNA in vivo after MBUS. 
 
 
 
Future work – optimization of MBUS in vivo 
 
Having a better understanding of the mechanisms involved in MBUS would 
undoubtedly lead to improvements in MBUS, however, in the absence of a detailed 
mechanism, MBUS can nevertheless be improved. Objective optimization of MBUS 
mediated gene delivery in vivo could be carried out using a wide range of parameters. 
In this study, the influence of a few variables was investigated (bubble concentration, 
bubble stability, acoustic settings and exposure times), which could form the basis of 
further optimisation efforts. Overall, results from this study lead to the hypothesis that 
for each microbubble there is a combination of parameters and settings that will lead 
to the most effective gene delivery. To test this, a wide range of experimental 
conditions will have to be investigated. The optimisation of the exposure duration 
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involves a complex interplay between the bubble durability in vivo with the 
destruction due to insonation, and as a result will be dependent on acoustic frequency, 
pressure amplitude, bubble type, size and concentration. It should also be tested if the 
optimum exposure time is defined by the persistence of the bubbles in the circulation. 
In other words, once the bubbles have been destroyed or have dissolved there is no 
benefit to continued acoustic exposure and conversely if the bubbles persist in the 
circulation after insonation is stopped then there could be opportunities for further 
enhancement. The effects of infusion versus bolus injection should also be 
investigated in this respect. In summary, the screening of several microbubbles and 
their parameters will provide knowledge on the optimum setting for each bubble for 
efficient and safe gene delivery. In combination with detailed acoustic and physical 
properties of the bubbles measured in vitro, insight into the mechanisms behind the 
process will also be possible. 
 
 If optimization and analysis of microbubbles gave an insight into which type 
of bubble is particularly useful for MBUS, this could be used to manufacture a 
microbubble specifically designed for use in MBUS rather than for the purpose of 
diagnostic imaging. Microbubbles commercially available to date were all designed 
to be used for diagnostic imaging and have not been designed for MBUS. Therefore, 
it is very likely that once the important characteristics for MBUS microbubbles are 
better understood, a microbubble can be designed purely for this purpose. This might 
include the attachment of ligands to the shell of the microbubbles which could 
improve on bubble-membrane proximity and also prolong the bubbles presence in the 
area of interest. 
 
 
Applications for MBUS 
 
In summary, MBUS has great potential to improve the efficiency of non-viral 
gene therapies. Factors that make this approach stand out from other physical 
enhancers is the ability to be site-specific, even though genetic material is injected 
systemically. The fact that the genetic material can be administered systemically 
while the ultrasound transducer targets gene delivery to the organs of interest allows 
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this technique to be adapted to a variety of treatments. Therefore, a wider range of 
application is possible compared to systems requiring injections directly into the 
target organ. The tissues that can be targeted with MBUS include kidney, spleen, 
thyroid, liver and heart and any other tissue that is within reach of the US beam.  In 
this study, mice were used as the pre-clinical model and due to their size, the depth of 
ultrasound penetration was not an issue. The depth of tissue penetration is however an 
important point that has to be considered when transferring MBUS application to 
clinical studies. Depth of US penetration depends on the frequency used. Higher 
frequencies are attenuated more by tissue than lower frequencies, therefore lower 
frequencies can penetrate deeper into the tissue. It is possible that US parameters, 
especially the frequency will have to be investigated on a larger animal model in 
order to ensure that the most appropriate ultrasound settings are found for optimum 
gene delivery as well as optimum tissue penetration. Moreover, the size of the 
transducer will have to be scaled up when larger organs are scanned. 
 
Although some research is still required in order to ensure a smooth translation 
from pre-clinical to clinical studies, MBUS does show potential as a physical 
enhancer for a variety of gene therapies. One promising application for MBUS is for 
the treatment of DMD. Results shown in chapter 5 have demonstrated that MBUS 
shows great potential to improve the systemic treatment of DMD through gene 
correction by antisense oligonucleotide (here PMO) mediated exon skipping. Uptake 
of naked PMO was sufficient to be able to achieve and maintain therapeutic levels of 
dystrophin in most muscles throughout the body when injected IV, with the exception 
of the heart174. The heart however is a crucial target for DMD therapy as cardiac 
mortality has recently replaced respiratory failure as the leading cause of death in 
DMD patients. Therefore there is a need to adapt the delivery of PMOs, so that the 
myocardium as well as all other muscles in the body can be successfully treated. 
When injections of PMOs were combined with MBUS to the heart (chapter 5) high 
levels of dystrophin-positive cardiomyocytes in the mdx heart were achieved. 
Although the exon skipping approach has certain advantages over methods that 
modify at the DNA level (e.g. no risk of insertional mutagenesis), PMO treatment 
may be less efficient as any dystrophin expression induced by PMO treatment will be 
transient in nature. As such, in order to be effective, PMO treatment needs to be 
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carried out repeatedly in conjunction with MBUS. This is not just the case for the 
injections with PMOs but also plasmid delivery, therefore the safety and practicality 
of this technique is paramount to its success. All histological analysis done in this 
study showed no sign of tissue damage in sections taken 24 hours after MBUS 
treatment, which allowed the conclusion that MBUS does not cause irreversible 
damage to cell membranes. The repeated treatment of mdx heart has shown that 
consecutive injections with MBUS resulted in the accumulation of dystrophin-
positive cardiomyocytes (chapter 5 &6). 
 
Although there still is further optimisation to do and certainly functional tests 
of the MBUS treated hearts would be desirable, the data presented here clearly 
demonstrate, MBUS can be successfully used to induce dystrophin-positive 
cardiomyocytes in the mdx heart whilst allowing PMO uptake in other muscles 
throughout the body. The data show that microbubble ultrasound is potentially a very 
valuable addition towards a complete systemic treatment of DMD using PMO-
mediated exon skipping. 
 
In summary, MBUS has the potential to treat a variety of diseases. Possible 
applications could be, for example, the delivery of vascular endothelial growth factor 
(VEGF). MBUS could be used to target VEGF to an area adjacent to a region of poor 
perfusion in the heart, thus promoting angiogenesis of the poorly perfused area. 
Another example would be the delivery of a plasmid expressing factor IX to the liver 
of patients with haemophilia. Clinical trials using viral vectors for this condition have 
run into problems with immune responses and destruction of transduced 
hepatocytes14, but such effects should be largely avoided by MBUS potentiated 
delivery of plasmid vectors. Applications are not however limited to the heart or liver. 
Tumours, skeletal muscle and kidneys are well within the application range for 
MBUS, for example for the delivery of plasmids encoding alpha-galactosidase A to 
kidney as a possible treatment for Fabry disease203. Overall, MBUS has the potential 
to be adapted to work with a wide range of gene therapy applications. It is a practical, 
non-invasive technique that is able to improve the delivery of genetic material in a 
systemic manner targeted at a specific site, tissue or organ. 
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9 Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9.1: Gel electrophoresis of PCR fragments after PCR of GFP in pEGFPluc 
and JAC1. Lane 1: 100bp ladder, lane 2: PCR fragment from pEGFPluc, lane 3: 
PCR fragment from JAC1. 
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Figure 9.2: Ex vivo bioluminescence imaging of mouse organs at day 7 after IV 
injection of 200µg pEGFPluc with MBs and 2minutes US to the heart. Colours 
represent intensity values given on scale bar.  
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Table 9.1: Video Intensity values of ultrasound images taken of microbubble 
solutions before and after a 20 second ultrasound exposure (H14MHz, MI 1.9 
using 15L8 transducer of Siemens Acuson Sequoia). 
 
 
 Video Intensity before US Video intensity after US 
SonoVue 1st 117.24 65.5 
2nd 117.06 71.9 
3rd 114.98 72.9 
Optison 1st 129.9 103.23 
2nd 130.65 98.8 
3rd 133.14 94.8 
Sonazoid 1st 120.07 80.8 
2nd 108.68 89.8 
3rd 111.3 83.2 
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Figure 9.3: B-mode ultrasound images of Optison taken (A) before 20 seconds of 
H14MHz US exposure (B) immediately after US exposure. 
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Figure 9.4: B-mode ultrasound images of Sonazoid taken (A) before 20 seconds 
of H14MHz US exposure (B) immediately after US exposure. 
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